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Abstract 
The development of cancer is a process by which an accumulation of genetic 
changes leads to uncontrolled replication of cells. Since the process of mutation is 
random, the set of alterations that occur and accumulate during tumorigenesis in one 
individual is different from that of another. These genetic differences drive tumor 
heterogeneity. One of the first technologies used to explore genome-wide heterogeneity 
was the microarray, which can be used to measure the expression of tens of thousands of 
genes. By exploring differences in expression of not just single genes, but groups of 
genes that may be altered in one set of tumors compared to another, researchers were 
able to classify subtypes of cancer that had relevance in disease aggressiveness, 
treatment, and prognosis. Furthermore, by looking at genome-wide patterns of 
expression, it is possible to identify specific oncogenic pathways that are activated and 
critical in driving tumor cell survival, growth, or metastasis. My research utilizes the 
patterns of expression derived from microarray analyses to study tumor heterogeneity, 
particularly in response to targeted cancer therapy, and mechanisms of cell death 
following oncogenic deregulation. 
One of the cancer types that has been explored through expression array analysis 
is B-cell lymphoma. Human aggressive B-cell non-Hodgkin lymphomas (NHL) 
encompass the continuum between Burkitt lymphoma (BL) and diffuse large B-cell 
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lymphoma (DLBCL), and display considerable clinical and biologic heterogeneity, most 
notably related to therapy response.  We previously showed that lymphomas arising in 
the Eµ-Myc transgenic mouse are heterogeneous, mirroring genomic differences 
between BL and DLBCL.  Given the clinical heterogeneity in NHL and the need to 
develop strategies to match therapeutics with discrete forms of disease, we investigated 
the extent to which genomic variation in the Eµ-Myc model predicts response to therapy.  
We used genomic analyses to classify Eµ-Myc lymphomas, link Eµ-Myc lymphomas 
with NHL subtypes, and identify lymphomas with predicted resistance to conventional 
and NF-κB targeted therapies.  Experimental evaluation of these predictions links 
genomic profiles with distinct outcomes to conventional and targeted therapies in the 
Eµ-Myc model, and establishes a framework to test novel targeted therapies or 
combination therapies in specific genomically-defined lymphoma subgroups.  In turn, 
this will rationally inform the design of new treatment options for aggressive human 
NHL. 
The second aspect of my thesis looks at the mechanisms of apoptosis following 
oncogene deregulation. The Rb-E2F pathway is a critical oncogenic pathway that is 
frequently mutated in cancers. Alterations in the pathway affect genome-wide 
expression in the cell, which in turn lead to deregulation of the cell cycle. The E2F1 
transcription factor regulates cell proliferation and apoptosis through the control of a 
considerable variety of target genes. Previous work has detailed the role of other 
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transcription factors that cooperate with E2F to mediate the specificity of E2F function.  
In this work, we identify the NF-YB transcription factor as a novel direct E2F1 target.  
Genome-wide expression analysis of the effects of NFYB knockdown on E2F1-mediated 
transcription identified a large group of genes that are co-regulated by E2F1 and NFYB.  
We also provide evidence that knockdown of NFYB enhances E2F1-induced apoptosis, 
suggesting a pro-survival function of the NFYB/E2F1 joint transcriptional program. 
Bioinformatic analysis suggests that deregulation of these NFY-dependent E2F1 target 
genes might play a role in sarcomagenesis as well as drug resistance.   
Taken together, these studies highlight the importance and power of analyzing 
genome-wide patterns of expression in investigating cancer heterogeneity, its ability to 
help predict treatment response, and its role in discovering the mechanisms behind the 
consequences of gene deregulation. 
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1. Introduction  
1.1 Molecular heterogeneity of cancer 
In their two seminal papers, Douglas Hanahan and Robert Weinberg proposed 
eight hallmark capabilities that all cancers needed: 1. Sustained proliferative signaling, 2. 
Resistance to cell death, 3. Evasion of growth suppressors, 4. Replicative immortality, 5. 
Induction of angiogenesis, 6. Activating invasion and metastasis, 7. Genome instability 
and mutation, and 8. Tumor-promoting inflammation, as well as two emerging 
hallmarks, deregulation of cellular energetics and avoidance of immune destruction (1, 
2). The development of cancer is the process of acquiring stochastic mutations, some of 
which will cause deregulation of various oncogenic pathways that confer tumorigenic 
capabilities that include uncontrolled proliferation and resistance to apoptosis signals, as 
mentioned in within the cancer hallmarks. Hence, the mutations that define the 
oncogenic process in one tumor will most likely be very different from the mutations 
that confer oncogenesis in another. This suggests that cancer is heterogeneous with 
differing sets of mutations leading to tumor characteristics that are unique within a 
group of tumors with a similar mutational profile.  
Ideally, each tumor could be sequenced and its set of defining mutations 
determined. However, the cost of genome wide sequencing has been prohibitively 
expensive until recent years (3). Although it is now financially feasible to sequence the 
genetic material of tumors, a different technology, the DNA microarray, has already 
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been extensively used for many years to study the differences in gene expression 
between different tumors and normal cells, leading to greater understanding of gene 
deregulation and tumor heterogeneity.   
1.1.1 DNA microarrays 
DNA microarray technology is based on both the dot blot, in which fragmented 
DNA from a sample of interest is transferred to a membrane, and then probed with a 
known DNA sequence of interest that is radiolabeled or fluorophore-labeled (4). 
Microarrays apply this technique to hundreds or thousands of DNA probes so that the 
presence and or quantity of many sequences of interest can be determined at the same 
time. Their first use was documented in 1982, when cDNA synthesized from induced 
mouse colon carcinoma RNA were cloned into E. coli. Clones were grown on 
nitrocellulose filters and screened with radiolabelled cDNA synthesized from 
polyadenylic acid-containing cytoplasmic RNA (messenger RNA) extracted from 
normal mouse colon, liver, kidney, or colon tumors (5). The relative brightness of the 
resultant spots on the filters was assessed to determine the relative expression of the 
clone sequences in the tumor and normal tissue samples. Later studies by the same 
group expanded the number of cloned sequences and showed differences between 
normal colon tissue, benign colonic adenomas, and colon carcinomas (6). This was also 
the first instance in which computer-based scanning and image-processing were used, 
which, given the increasing number of clones, became necessary for efficient data 
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collection. A few years later, the same group used arrays with even more sequences and 
found a set of thirty clones, possibly the first multi-gene signature, that differentiated 
normal colonic mucosa of low risk individuals from normal colonic mucosa of high risk 
individuals who had familial adenomatous polyposis or hereditary nonpolyposis colon 
cancer (7). 
Inter-tumor cancer heterogeneity has been recognized by the scientific 
community for a number of decades and certainly before the use of microarrays. 
However, microarrays allowed for the first time the determination of tumor gene 
expression on a genome-wide level. Also, with the miniaturization and development of 
spotted arrays on glass slides, in which small microscopic drops of oligonucleotide 
probes could be positioned in very close proximity, it was now possible to assay more 
genes with less sample material (8). In 1999, Eric Lander’s group at Harvard, using 
commercial arrays, showed that expression arrays can be used to discover distinctions 
between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), two 
diseases which at that point were difficult to accurately differentiate clinically (9). The 
following year, Brown and Staudt’s group at Stanford, using their own high density 
arrays, defined novel germinal center B-cell (GCB) and activated B-cell (ABC) subtypes 
of diffuse large B cell lymphoma, a disease which had previously been treated clinically 
as a single entity (10). These subtypes reflected the lymphomas’ cell of origin and 
demonstrated drastically different clinical prognoses. That same year, they assessed 
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human breast cancer and were able to classify them into several subtypes based on the 
differences in their pattern of gene expression as well as show differences in clinical 
outcomes (11). Subsequent studies have used similar methods to “profile” lung cancer 
(12, 13), prostate cancer (14), and others. By studying the patterns of gene expression 
that define specific “molecular” subtypes of various cancers, it was feasible to look at 
what oncogenic pathways might be affected by the set of mutations within a certain 
tumor. 
1.1.2 Pathway-based heterogeneity 
Since gene expression profiling of cancers began, researchers were also looking at 
how to classify new tumors into the identified subgroups. When Eric Lander’s group 
showed through gene expression that AML and ALL can be distinguished, they also 
used the genes whose expression patterns differentiated the two cancers to generate a 
predictive model in which new tumors could be assigned to one group or another (9). 
Hence, the concept of a gene signature, a set of genes in which expression is correlated 
with one state or another, was applied to studying cancer. Subsequently, the same 
research group generated a gene expression signature for metastasis that was derived 
from a comparison of primary adenocarcinomas and metastases (15). This signature was 
further demonstrated to stratify tumors which were likely to be associated with 
metastasis and hence showed poor clinical prognosis. A group at the Netherlands 
Cancer Institute under René Bernards generated a signature that predicted the 
 5 
likelihood of breast cancer metastasis and was also linked to clinical outcomes (16, 17). 
Signatures were also applied to study the patterns of gene expression changes following 
oncogene deregulation. By assessing gene expression patterns across hundreds of 
tumors, the Harvard group extracted a signature for cyclin D1 overexpression (18). 
Leveraging the idea of the expression of entire pathways being altered following 
oncogenic alterations, researchers sought to mimic the effect of the activation by 
particular oncogenic mutations or of oncogenic pathways via genetic manipulation or 
growth factors.  The Nevins group at Duke used adenoviruses containing an oncogene 
(Myc, Ras, E2F1, E2F2, E2F3) or a negative control and compared the patterns of 
expression. The resulting expression changes should represent those genes whose 
expression varied across samples in a way that segregated oncogene-deregulated from 
control samples (19). These gene signatures were able to accurately calculate when a 
pathway was activated during the cell cycle based on the patterns of gene expression at 
that point in the cycle. This work was further expanded with additional oncogenic 
pathways such as Src and β-catenin. More importantly, the signatures were able to 
accurately predict the likelihood and degree to which an oncogenic pathway was 
activated in tumors (20). As an example, MYC-driven mouse tumors from MMTV-Myc 
mice showed high Myc pathway activation compared to HER2 driven, Rb null, or wild 
type tissue. Similarly, Rb null tumors showed the highest E2F3 pathway activation 
compared to other tumor types, consistent with Rb inhibition of E2Fs. In non-small cell 
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lung cancer, the Ras signature was significantly higher in tumors bearing a Ras 
activating mutation. Furthermore, profiling based on patterns of pathway activation 
rather than raw expression data can not only separate tumors into subgroups, but also 
provide information on pathways likely to be active and driving growth of the tumor 
(21).   
Similar pathway signature-based approaches have be also used to analyze non-
genetic factors, such as tumor microenvironmental stresses, studied by the Chi lab at 
Duke and other groups. Several examples include gene signatures of cell-type specific 
hypoxia response that delineate a subset of tumors with strong hypoxia response and 
poor outcomes in several types of cancers (22-26). The Chi group also developed a 
signature for lactic acidosis (LA) response, distinct from hypoxia response, that 
recognizes tumors with more favorable outcomes due to its ability to inhibit Akt and 
glycolysis and trigger starvation responses (27, 28). One critical mediator of LA response 
is TXNIP (28), which inhibits glycolysis and exhibits many anti-tumor properties (29-32).  
The gene signature approach enables the integrative analysis of non-genetic 
stress pathways with oncogenic signaling pathways. This has allowed the identify 
dramatic metabolic differences between basal and luminal types of breast tumors.  
Basal-type cells have an exaggerated hypoxia response due to high HIF-1α/HIF-2α 
mRNA levels (33) and are addicted to glutamine and thus susceptible to glutamine 
deprivation (34). Results from the Chi group also suggest that sub-signatures of the 
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hypoxia/LA responses appear to be driven by DNA copy number alterations (CNAs). 
These CNAs significantly associate with the hypoxia/LA response in tumors and may 
regulate and possibly be selected by these stresses (35). For example, a CNA that shows 
significant negative association with the hypoxia response contains FH and EGLN3, 
which code for proteins that negatively regulate HIF-1α (35), a transcription factor 
essential in cellular response to hypoxia. Similar to oncogenic signatures defined by the 
deregulation of oncogenes and tumor suppressors, the study of the tumor 
microenvironment provides another layer with which to examine tumor heterogeneity 
and the driving forces behind oncogenesis and tumor survival. 
Importantly, with the development of cancer therapies that target specific 
oncogenic proteins rather than killing dividing cells, as is the case with chemotherapy or 
radiation therapy, it has become important to understand what pathways are important 
in the survival and growth of a tumor. This has made microarrays and expression 
signatures an important tool for identifying which cancer patients would be sensitive to 
which therapies. 
1.1.3 Targeted cancer therapeutics 
Targeted therapy is an important and relatively new treatment modality that 
recognizes and treats the heterogeneity inherent in cancer. In contrast to the traditional 
cytotoxic chemotherapy, which uses toxins to preferentially kill rapidly dividing cells, 
targeted therapies inhibit specific protein functions within a cancer cell, particularly 
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those that have been deregulated as a result of mutations known to drive oncogenesis or 
promote tumor survival. They are somewhat similar to hormonal therapy, a modality in 
which the exogenous administration of hormones, in particular steroid hormones, is 
used against cancers that rely on a hormone pathway for growth. There are several 
classes of targeted therapies including tyrosine kinase inhibitors, serine/threonine kinase 
inhibitors, and monoclonal antibodies. 
Tyrosine kinase inhibitors (TKI) are small molecules that act against the 
phosphorylation activity of kinases that phosphorylate tyrosine residues on target 
proteins.  Deregulated tyrosine kinase activity has been recognized as a key driver of 
oncogenesis and cancer survival and proliferation. In fact, some cancers, such as chronic 
myelogenous leukemia, based on their response to tyrosine kinase inhibitors, seem to be 
strongly if not completely dependent on a specific deregulated tyrosine kinase. This 
dependence was termed “oncogene addition” (36). 
TKIs were first introduced clinically with imatinib (Gleevec) to treat chronic 
myelogenous leukemia. In the majority of CML tumors, there is a reciprocal 
translocation between chromosome 9 and 22, called the Philadelphia chromosome, 
which juxtaposes ABL1, a proto-oncogenic tyrosine kinase, with a portion of breakpoint 
cluster region protein (BCR) (37). This creates a tyrosine kinase that is constitutively 
active. Upon treatment with Gleevec, CML patients with the BCR-ABL fusion protein 
are effectively cured of their disease. Since then, over a dozen other TKIs have been 
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introduced clinically. Gefinitib (Iressa) and erlotinib (Tarceva) target EGFR and are used 
in the treatment of non-small cell lung cancer. Lapatinib is a dual EGFR/HER2 inhibitor 
used in the treatment of breast cancer. TKIs that target VEGFR, important in 
vasculogenesis and angiogenesis (38), SRC, and MET, as well as other tyrosine kinases, 
are used to treat various cancers and other diseases driven by tyrokine kinase 
deregulation (reviewed in (39)). Many tyrosine kinases now have inhibitors at the 
research and development or clinical trial phase of development, such as ALK, which is 
translocated in many anaplastic large-cell lymphomas as well as some non-small cell 
lung cancers, and ROS, also found to be rearranged in some non-small cell lung cancers 
(40).  
Serine/Threonine kinase inhibitors target the function of kinases that 
phosphorylate serine or threonine. Serine/threonine kinases (STK) themselves play 
important roles in regulating cell proliferation, growth, survival and protein synthesis 
and have been found to be mutated or deregulated in cancers (41, 42). STK inhibitors are 
not as numerous clinically as TKIs. Currently, there are small molecule inhibitors 
targeting BRAF, found to be mutated in some human cancers (42), MEK, and mTOR 
approved in the treatment of renal cell carcinoma, breast cancer, and melanoma as well 
as other non-cancer diseases. Similar to TKIs, numerous small molecules are in drug 
development pipelines targeting many of the kinases within the family. 
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Monoclonal antibody therapy is unique from kinase inhibitors in that it takes 
advantage of biological molecules, in this case antibodies that can stimulate a patient’s 
immune system to attack cells bound by those antibodies. The technology originated 
with the development of hybridomas, hybrid cell lines fusing a B cell that produces 
antibodies with a myeloma (43). This created an immortal cell line that produced 
monoclonal antibodies. With the subsequent development chimeric, humanized, and 
human antibodies that can be produced by transgenic mice or phage display libraries, 
the resulting antibodies had greater serum half-life and binding affinity to their human 
targets, as well as reduced risk of allergic reactions (44-46).  
The first definitive evidence showing that monoclonal antibodies could work 
was their use to target cells that had been transformed by Her2 (47-49), a receptor 
tyrosine kinase responsible for activating various signaling pathways that promote cell 
proliferation and inhibit apoptosis. HER2 is amplified or overexpressed in 
approximately 20% of breast cancers (50). Since then, over thirty have been approved for 
diseases ranging from autoimmune disease to asthma. In 1997, rituximab became the 
first antibody approved to treat human cancer.  Targeting CD20, a B cell antigen 
expressed beginning at the pro-B phase and increasing in concentration as the cell 
matures (51), the chimeric antibody was indicated for non-Hodgkin lymphoma. Along 
with cyclophosphamide, doxorubicin, vincristine, and prednisone, it has become the 
standard therapy for treatment of most non-Hodgkin lymphomas. This was followed by 
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trastuzumab, a humanized HER2 antibody for breast cancer treatment, the first to be 
approved for the treatment of solid tumors. Because HER2 is overexpressed in only a 
subset of cancers, companion diagnostic tests based on immunohistochemistry were 
established to determine if a breast tumor had an overabundance of HER2 receptors on 
its cell membranes. Because its efficacy and use in a subset of breast tumors, 
trastuzumab became the poster child for the promise of targeted therapeutics. 
Subsequent cancer treating monoclonal therapies have been indicated for use in acute 
myelogenous leukemia (CD33), chronic lymphocytic leukemia (CD52), colorectal and 
non-small cell lung cancer (VEGF and EGFR), head and neck cancer (EGFR), and 
melanoma (CTLA-4). 
With the ability of monoclonal antibodies to bind cancer cells that overexpress 
their targets, having a cytotoxic drug conjugated to the antibody would allow the 
targeted delivery of chemotherapies directly to cancer cells. Anti-body drug conjugates 
(ADC) have made this a reality. They not only allow for chemotherapy discrimination 
between normal and malignant tissues, but also decrease the potentially damaging side 
effects associated with systemic exposure to cytotoxic agents and increase the dosage 
that can be used, enhancing chemotherapy effectiveness. More than two dozen ADCs 
are in various stages of development, with two, a CD30 antibody-antitubulin conjugate 
(brentuximab vedotin) approved for treatment of hogdkin’s lymphoma and anaplastic 
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large cell lymphoma and Trastuzumab emtansine, a HER2-antitubulin conjugate 
indicated for treatment of HER2-positive breast cancer (52). 
As a standalone therapy or in combination with existing hormonal or cytotoxic 
therapies, targeted therapies have accounted for many of the enhancements in cancer 
patient survival while reducing side effects. They remain one of the main areas of focus 
for many pharmaceutical and biotechnology companies with hundreds of drugs at 
various stages of the developmental pipeline. Unfortunately, the tumor heterogeneity 
that ushered in the development of targeted therapies is also what makes targeted 
therapies similar to chemotherapy and hormonal therapy, the development of drug 
resistance. The stochastic mutations that cause one tumor to differ from another can also 
generate two or more subpopulations of cells to arise within a tumor, one sensitive and 
one resistant to therapy. Hence, it becomes important to understand the breadth of 
oncogenic mutations within tumors to fully leverage the power of targeted therapies. 
 
1.2 c-MYC oncogene and Mouse Models 
The Myc oncogene was discovered in the late 1970’s through research on 
fulminant chicken tumors (53, 54). Since then, it has been recognized as a central 
transcription factor involved in cell growth, proliferation, tumorigenesis, and even stem 
cells. Because of its importance, Myc expression is highly regulated at the mRNA levels 
by numerous mechanisms involving regulatory motifs in its promoter (55, 56) and its 
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protein stability is tightly controlled through the Ras-mediated Raf-MEK-ERK kinase 
cascade and PI3K-Akt pathway that inhibits GSK-3β (57). In tumorigenesis, it was 
determined early on that MYC was frequently translocated in Burkitt’s lymphoma (58, 
59). In addition, Myc is frequently amplified or upregulated in many tumors such as 
breast, colorectal, pancreatic, gastric, uterine, and ovarian cancers (60, 61). Therefore, 
Myc is considered one of the most frequent genetic alterations found in human cancer 
(62).  
However, deregulated Myc expression in and of itself is not sufficient for 
tumorigenesis. Enforced Myc expression actually induces apoptosis through a 
combination of ARF induction, leading to p53 accumulation and relieving the cell of 
MDM2-dependent feedback (63), and the suppression of antiapoptotic BCL-2 and BCL-
xL (64, 65). Because of this tendency of Myc over-expression to cause cell death, it was 
hypothesized that the complete malignant transformation would require a cooperating 
“second hit”, another mutation or set of mutations that reduces the apoptotic potential 
of Myc. 
1.2.1 Myc mouse models 
Mouse models have contributed greatly to the understanding of Myc as an 
oncogene. One of the earliest models coupled mouse Myc to the mouse mammary tumor 
virus promoter (MMTV-Myc) (66). These mice develop spontaneous mammary 
adenocarcinomas and various iterations of the transgenic line have been used to study 
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cell cycle regulation (67), tumor development (68), and heterogeneity (69).  Myc by itself 
is not sufficient for tumorigenesis, as evidenced by the fact that tumors develop 
spontaneously, presumably after the second hits, rather than uniformly following Myc 
induction. Myc serves to drive overgrowth of cells that increases the chances a 
tumorigenic mutation occurs that allows for tumor development. 
Another model couples Myc to the immunoglobulin heavy chain enhancer (Eμ-
Myc) (70), mirroring the translocation seen in Burkitt’s lymphoma. Mice from the 
resulting transgenic line develop B-cell lymphomas that arise from both immature and 
mature B lymphocytes. Similar to MMTV-Myc mice, Myc in this case is also not 
sufficient for tumorigenesis. Constitutive Myc expression leads to an expanded 
population of pre-B cells in which a “second hit” may occur, causing tumors to arise at 
random (71). Clonality experiments have shown that multiple cells can undergo 
tumorigenesis concurrently, leading to tumors that arise from two or more pre-B and B 
cells. The second hit has been well studied in the Eμ-Myc model. Mutation analysis of 
Eμ-Myc tumors has also born out the need for coordinating genetic alterations that 
decrease the apoptotic potential of Myc overexpression. The majority of arising tumors 
contain mutations that either disrupt the ARF-MDM2-p53 pathway (63, 72, 73) or cause 
overexpression of pro-survival BCL-2 or BCL-xL (64, 65, 74). In fact, about 80% of 
lymphomas that arise from the Eμ-Myc model have an alteration in the p53 axis, 
whether it be deletion of ARF (24%), mutation or loss of p53 (28%), or Mdm2 
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overexpression (48%) (63). In this pathway, ARF binds to and sequesters Mdm2 (75, 76), 
which normally functions to inhibit p53 transactivation (77) and target p53 for 
degradation by ubiquitination(78, 79). Mdm2 is also a p53 transcriptional target, 
providing a negative feedback mechanism regulating p53 function (80, 81). BCL-2 and 
BCL-xL are often overexpressed in a number of human cancers including non-
Hodgkin’s lymphoma, colorectal, gastric, prostate, and non-small cell lung cancers, and 
neuroblastomas (reviewed in (82)). 
The second-hit model is further supported by results from double transgenic 
animals. Eμ-Myc mice crossed with mice in which the ARF locus is deleted display 
much faster lymphomagenesis through suppression of p53 (83). When BCL-2 is also 
placed under transcriptional control of the immunoglobulin heavy chain enhancer, the 
resulting transgenic mice when crossed with Eμ-Myc mice also show faster tumor 
development (74). On the other hand, mice deficient in Mdm2 binding protein (MTBP), 
which increases p53 degradation through increasing Mdm2 ubiquitin ligase activity, 
when crossed into the Eμ-Myc model show delayed lymphoma development (84). Taken 
together, these results indicate the clear need for additional alterations to induce 
tumorigenesis and that these alterations frequently occur in the p53 axis or BCL2 family. 
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1.3 The E2F family 
The E2F family is a group of transcription factors that are downstream effectors 
of the tumor suppressor, retinoblastoma (Rb). There are eight genes and nine proteins 
within the E2F family, which function in many biological processes including DNA 
replication and repair, mitosis, mitotic and DNA-damage checkpoints, differentiation, 
development, and apoptosis (85-87). E2F1, E2F2, and E2F3a are considered the activator 
E2Fs because of their main role in activating gene transcription, while E2F3b and E2F4-
E2F8 constitute the repressor E2Fs because of their function in repressing gene 
expression. Many E2F members have also been closely tied to the oncogenic process. 
Rb, an important regulator of the E2F family, was first identified because of its 
association with a heritable eye tumor, retinoblastoma (88, 89). In non-proliferating cells, 
Rb is bound to the E2Fs, which suppresses their function (90-96). The binding of Rb to 
E2Fs also represses transcription through recruitment of histone deacetylases, histone 
methyltransferases, and DNA methyltransferases to the promoters of E2F target genes 
(97). Following growth stimulation, Rb is phosphorylated by a complex of cyclin D and 
cyclin dependent kinase 4 (CDK4) or cyclin D and CDK6 (98). This hypophosphorylated 
Rb can no longer bind the E2Fs, thus allowing E2F to trigger a transcriptional cascade 
that leads to progression through the cell cycle. Deregulation of the Rb-E2F pathway, 
whether through loss of Rb function, cyclin D amplification, or p16/CDKN2A (CDK 
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inhibitor) loss resulting in Rb hyperphosphorylation occurs in the majority of human 
cancers (99).  
Following mitogenic stimulation, activator E2Fs are released to target 
transcription of many genes involved in cell-cycle progression such as cdc6, an essential 
DNA replication regulator that has an important role in activating cell cycle checkpoints 
leading to S phase and mitosis (100), Cyclin E, whose binding to CDK2 in G1 phase is 
required for transition to S phase and determining cell division (101), and DNA 
polymerases.  
Studies deregulating expression of the activator E2Fs have highlighted their 
importance in the cell cycle. For example, cells in which E2F1, E2F2, and E2F3 are lost 
show impaired expression of essential cell-cycle progression genes that are E2F targets 
and exhibit an inability to progress through the cell cycle (102). Similar to Myc, 
deregulation of E2Fs are also tied to the p53 axis. Under normal circumstances, ARF is 
repressed, allowing Mdm2 to bind to and inactivate p53. However, in E2F3 deficient 
cells, ARF is derepressed (103), leading to p53 activation and defects in the cell cycle 
including upon re-entry into the cell cycle from quiescence. ARF loss, however, 
abrogates these defects in E2F3 cells. ARF also activates transcription of E2F 
transcriptional-repressor complexes, leading to inactivation of activator E2Fs (104). Also, 
cells without E2F1-E2F3 exhibit p53 activation and interestingly, will express E2F target 
genes upon loss of p53 (105). Hence, cell proliferation is regulated by E2F through the 
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p53 axis and consequent induction of repressor E2Fs. Deregulation of E2Fs, in and of 
itself, is often insufficient to cause tumorigenesis and requires a second hit, often in the 
p53 axis, for cancer development. 
1.3.1 E2F1 
Among the activator E2Fs, E2F1 is unique in its ability to directly induce 
apoptosis, as seen when E2F1 is ectopically expressed (106). This is further evident in the 
fact that mice deficient in E2F1 will develop tumors in part because of the lack of E2F1-
mediated apoptosis (107).  E2F1 can induce apoptosis both through p53 and also 
independently of p53.  
In p53-dependent apoptosis, abnormal E2F1 expression can stabilize and activate 
p53 to cause apoptosis by multiple mechanisms. First, E2F1 may activate ARF 
expression that leads to p53 stabilization and activation (108). Additionally, E2F1 can 
also induce p53 phosphorylation at certain amino acids that is normally seen in response 
to DNA damage (109, 110), leading to p53 activation in an ARF-independent manner. 
E2F1 can also upregulate p53 co-factor (ASPP1 and ASPP2) expression that directs p53 
towards activating pro-apoptotic genes and subsequent apoptosis (111-113). Rb is also a 
participant in E2F1-mediated apoptosis through p53, as Rb inactivation will induce p53-
mediated apoptosis. This can be inhibited by loss of E2F1 (114). This link between the 
Rb-E2F pathway and the p53 pathway can be seen in the fact that because Rb 
 19 
inactivation leads to deregulated E2F1 and subsequent E2F1 mediated apoptosis, a 
cooperating mutation in the p53 axis often occurs with Rb loss in tumors (99, 115).  
E2F1-induced apoptosis that is independent of p53 occurs through a variety of 
pathways. E2F1 activates expression of APAF1 (116), which binds to cytochrome c and 
ATP to form an apoptosome that cleaves and activates caspase 9 to stimulate the caspase 
cascade, committing the cell to apoptosis (117, 118). E2F1 also upregulates other 
caspases as well as p73 (116), structurally related to p53 and involved in apoptosis (119). 
It also directly upregulates Bcl-2 homology 3 (BH3)-only genes, which are proapoptotic 
Bcl-2 family members, such as PUMA, Noxa, and Bim (120). Along with upregulation of 
pro-apoptotic genes, E2F1 also represses expression of survival signals mediated by NF-
κB and BCL-2 (116). 
Given E2F1’s potential to induce both proliferation and apoptosis and its 
importance in initiating the cell cycle, the apoptotic arm of E2F1 must be tightly 
regulated. Rb has a domain called the Rb pocket that binds E2Fs. It has an additional 
binding site that binds E2F1, which specifically inhibits E2F1-mediated apoptosis (121). 
Following DNA damage, this region of Rb becomes acetylated, releasing E2F1 without 
affecting Rb binding to other E2Fs (122). E2F1 also becomes acetylated following DNA 
damage and these changes favor the induction of pro-apoptotic E2F1 targets such as p73 
(123). Moreover, cells deficient in E2F1 show reduced apoptosis following DNA 
damaging chemotherapy treatment (124, 125). These reports indicate that E2F1-mediated 
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apoptosis is a response of DNA damage. E2F1 binding partners also mediate E2F1-
induced apoptosis. Jab1 binds to the E2F1 marked box domain, one that has 
proapoptotic activity unique to E2F1 (126), and its interaction with E2F1 directs 
expression of proapoptotic genes (127). Similarly, Foxo1 and Foxo3 also bind E2F1 to 
direct a proapoptotic transcriptional program that includes APAF1 and CDKN1C (128). 
API5, an apoptosis inhibitor, is another mediator of E2F1-induced apoptosis but does 
not serve to inhibit E2F1-mediated transcription (129).  
Pathways are also involved in the regulation of E2F1-induced apoptosis. The 
PI3K-Akt pathway in particular, specifically inhibits this activity. When PI3K, a family 
of signal transducing kinases, is activated by growth factors such as IGF1, it activates 
Akt, serine/threonine kinase (130). Akt affects E2F1-induced apoptosis by 
phosphorylating TopBP1, allowing it to bind E2F1 and repress E2F1-induced apoptosis 
(131). The PI3K-Akt pathway also inhibits E2F1-mediated apoptosis by repressing E2F1 
targets involved in the process (132). Breast and ovarian cancers that exhibit low 
expression of this specific set of genes show worse prognoses. Summarily, E2F1-
mediated apoptosis is a tightly controlled process normally induced by DNA damage or 
expression of E2F1 without growth signals. When the process of E2F1-induced apoptosis 
is deregulated through mutations that affect any of the genes or pathways mentioned 
above, cells are subsequently desensitized to apoptosis, providing an opportunity for 
deregulated growth and tumorigenesis. 
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2. Genomic analysis of the Eμ-Myc mouse as a model 
for heterogeneity in therapeutic response 
2.1 Introduction 
Aggressive B-cell lymphomas include a spectrum of diagnoses that span Burkitt 
lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and lymphomas that lie 
between these diagnoses, termed by the World Health Organization 2008 classification 
as “B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and 
BL”(133). There is considerable clinical and therapy response heterogeneity across and 
within these diseases. While diffuse large B-cell lymphoma is generally responsive to the 
R-CHOP chemo-immunotherapy regimen (containing rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone) that is commonly used for treatment of non-
Hodgkin’s lymphoma, Burkitt’s lymphoma requires more aggressive multi-agent 
regimens that are accompanied by higher toxicities. Although these lymphoma subtypes 
are generally treated differently, patients are not always cured and responses are not 
always complete. Prior studies evaluating the heterogeneity of aggressive B-cell 
lymphomas using primary patient samples have begun to highlight that biologic and 
genomic complexity underlies clinical variation (10, 134-137). More recently, exome, 
RNA, and whole genome sequencing have highlighted the recurrent and presumably 
driver mutations that frequently occur in BL and DLBCL and that many mutations are 
specific to BL or a subtype of DLBCL (138-142). Currently, these studies have pointed to 
possible biomarkers to aid in therapy selection. None have yet made it to clinical use, 
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however. The inherent limitations in the availability and quality of patient-derived 
samples suggest that experimental models could greatly facilitate efforts to understand 
heterogeneity in aggressive lymphomas and in therapy response and to develop 
appropriate therapeutic options.  
Genetically engineered mouse models have provided significant insight into 
human cancer biology. These models result from the activation or loss of a single gene, 
and are generally considered to represent a distinct and homogenous phenotype.  
However, our previous work has provided evidence of heterogeneity in genetically 
engineered mouse models, specifically the MMTV-Myc model of breast cancer and the 
Eμ-Myc model of B-cell lymphoma (69, 143). In both cases, large numbers of tumors 
from these transgenic mice were evaluated and found to have natural heterogeneity in 
histologic characteristics and genome-scale expression data exists, suggesting secondary 
genetic hits drive variation in genetically engineered mouse models. 
The Eµ-Myc transgenic mouse was developed as a model of Myc-driven aggressive 
B-cell lymphoma (70, 71). Multiple investigations have identified genes that alter the 
onset of Eµ-Myc lymphoma and/or affect response to single agent chemotherapy (74, 
144-151). The Eµ-Myc model has also been used in a genetic screen to identify genes that 
modulate response to doxorubicin (152). By focusing largely on perturbing single genes 
in the Eµ-Myc background, these studies did not focus on the effects of gene networks 
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and their relevance to the natural genetic heterogeneity seen in the Eµ-Myc model, 
particularly as it pertains to response to lymphoma therapy. 
While the Eμ-Myc model does show similarities to human disease, there are a 
number of limitations. Cell of origin is one such shortcoming. The majority of Eμ-Myc 
tumors tend to be pre-B in surface marker expression, owing to the transgene causing 
clonal expansion of pre-B cells, with a minority being mature B cells (71). DLBCL, on the 
other hand, is predominantly derived from mature B cells, whether they be germinal 
center of activated B cell, and BL are typically germinal center B cells. Furthermore, 
exome, RNA, and whole genome sequencing have shown recurrent gene mutations, 
some of which are enriched in BL or a subtype of DLBCL, such as ID3 in BL, EZH2 in the 
germinal center B-cell like subgroup of DLBCL, and MYD88 in the activated B-cell like 
subgroup of DLBCL (138-142). Lack high-throughput sequencing in Eμ-Myc tumors has 
prevented a comparison with the complexity of the mutational landscape in human 
lymphoma. 
We previously described that the Eµ-Myc transgenic mouse model of lymphoma 
develops genomically distinct lymphoma subtypes that reflect the spectrum of human 
aggressive B-cell lymphomas (143). Here, we describe a genomic analysis strategy to 
reproducibly classify the distinct forms of Eµ-Myc tumors and methods to use the Eµ-
Myc lymphoma model to predict therapy response. 
 
 24 
2.2 Materials and Methods  
2.2.1 Mouse strains and tumor monitoring 
Eµ-Myc strain (JAX stock# 002728) and C57BL/6J strain (JAX stock# 000664) mice 
were purchased from Jackson Laboratories, and were bred and housed in a Duke 
University Medical Center Division of Laboratory Animal Resources facility. All 
experiments were approved by the Duke University Institutional Animal Care and Use 
Committee. Eµ-Myc mice were monitored twice weekly for visible or palpable lumps, a 
hunched posture, tachypnea, a swollen belly, or ruffled fur. Upon development of such 
symptoms, mice were sacrificed and dissected. The spleen and enlarged lymph nodes or 
masses were removed and placed in RPMI media (GIBCO) with 10% heat-inactivated 
fetal bovine serum (FBS, Sigma). Spleens were weighed and lymph node specimens 
were frozen in liquid nitrogen or fixed in 10% formalin. Single cell suspensions were 
generated from remaining tissue by squeezing between ground glass slides and filtering 
the suspension through a sterile 100 μm cell strainer (BD Falcon). Thereafter, we lysed 
red cells in the cell suspensions and washed the cells twice. Lymphoma cells were either 
stored inviably at -80°C as cell pellets or resuspended in freezing media (10% DMSO 
(Sigma) in heat-inactivated FBS), aliquoted, and stored viably in liquid nitrogen. 
2.2.2 Generation of Eμ-Myc lymphoma in C57BL/6 mice and treatment 
To transplant Eµ-Myc lymphomas to C57BL/6 mice, we thawed and washed 
frozen Eµ-Myc lymphoma cells and determined the viable cells. We suspended the 
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lymphoma cells in RPMI media (GIBCO) and injected 5x105 lymphoma cells by the i.p. 
route into C57BL/6J mice. We monitored recipient mice daily, and rated illness on a scale 
from 1 to 5, where 1 was moribund, 3 was obvious lymphoma, and 5 was perfect health. 
Mice with a rating of 3 were either sacrificed or treated with chemotherapy – 
cyclophosphamide (300 mg/kg i.p. once), doxorubicin (10 mg/kg i.p. once), or bortezomib 
(1 mg/kg i.p. twice weekly for four doses) – and were thereafter monitored daily using 
the rating scale until progression (score less than 3), at which time they were sacrificed 
and lymphoma tissue was collected. Cyclophosphamide and doxorubicin were 
purchased from the Duke University Medical Center inpatient pharmacy, and 
bortezomib was purchased from LC laboratories.  
2.2.3 Gene expression profiling data preparation and normalization 
Lymphoma tissue samples were homogenized using the Lysing Matrix A tube 
for tissue (MP Biomedicals). Lymphoma cell pellet samples were homogenized by 
passing through a tuberculin syringe and centrifuged through a QIAshredder 
homogenizer column (Qiagen). RNA was extracted from the lysates using Qiagen 
RNeasy kits (Qiagen). RNA integrity was verified with an Agilent 2100 Bioanalyzer. 
Microarray processing and RNA hybridization to Affymetrix Mouse 430 2.0 or Mouse 
430A 2.0 GeneChip arrays were performed according to the manufacturer’s instructions 
in the Duke University DNA microarray core facility.  
 26 
From microarray CEL files, data was normalized with either MAS5 or RMA 
algorithms for appropriate downstream analyses. Gene expression data can be accessed 
in the NCBI Gene Expression Omnibus (GSE40760). For analyses comparing data 
obtained from microarrays processed at different times (separate batches), the ComBat 
algorithm (153) was used to reduce batch effect. For analyses comparing human and 
mouse microarray data, we used ChipComparer1 and FileMerger2, as described 
previously (69). 
2.2.4 Microarray analysis 
We performed unsupervised analyses of unfiltered genomic data from Eµ-Myc 
lymphomas using the k-means clustering algorithm. For supervised analyses, we 
determined which genes were differentially expressed between the two clusters using 
the Wilcoxon rank sum test and Bonferonni correction (q value < 0.2). Gene ontology 
and biological function of differentially expressed genes was assessed using DAVID3, 
and significant gene ontology terms were selected from Bonferonni values less than 10-5. 
We also used genomic data to develop new genomic models (“signatures”) from 
existing microarray datasets using the binary regression (Binreg) algorithm (for two-
class models) (20, 154) or Prediction Analysis for Microarrays (PAM; for greater than 
two-class models (155). Datasets used to generate and validate signatures along with 
                                                     
1 http://chipcomparer.genome.duke.edu/ 
2 http://filemerger.genome.duke.edu/ 
3 http://david.abcc.ncifcrf.gov/home.jsp 
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accuracy of the signature using leave-one-out cross validation are listed in Table 1. 
Parameters used in generating genomic signatures are listed in Table 2.  Genomic 
signatures of cellular pathway activation were applied using the ScoreSignature module 
(156) on the Duke University GenePattern server. 
 
Table 1: Datasets used for genomic analyses 
Database Dataset Number Signature Training Set or 
Validation Set 
Accuracy by 
Leave-One-Out 
Cross Validation 
GEO GSE7897 E-Myc Cluster Training 97% 
GEO GSE4475 GCB-ABC; CHOP 
resistance 
Training 100%, 84% 
GEO GSE10846 GCB-ABC; CHOP 
resistance 
Validation Not Applicable 
GEO GSE26408 B-cell maturation Training 96% 
 
Table 2: Parameters used for genomic signature generation and application 
with BinReg algorithm 
Signature Genes 
(N) 
Factors 
(N) 
Burn-in Iterations Quantile 
Normalize? 
Standardize? 
E-Myc 
Cluster 
500 2 1000 5000 Y Y 
GCB-ABC 200 2 1000 5000 Y Y 
CHOP 
Resistance 
200 2 1000 5000 Y Y 
 
2.2.5 Immunoblot analysis 
Protein was extracted from frozen lymphoma tissue and immunoblots were 
performed as described previously (147). 100 μg protein samples were fractionated by 
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gel electrophoresis and transferred to Immobilon membrane to detect c-MYC, p19ARF, 
MDM2, p53, p65/RELA, phosphorylated p65/RELA, β-Actin, and GAPDH. Antibodies 
used were as follows: c-MYC (Santa Cruz N-262 sc 764, 1:500), p19ARF (Calbiochem Ab-1 
PC435, 1:1000), MDM2 (Santa Cruz c-18 sc812, 1:1000), p53 (Calbiochem Ab-1 OP03, 
1:1000), p65/RELA (Santa Cruz C-20 sc-372, 1:1000), phosphorylated p65/RELA (Cell 
Signaling 93HI 3033S, 1:1000), β-Actin (Cell Signaling 13E5 4970S, 1:5000), and GAPDH 
(Santa Cruz FL-335 sc-25778, 1:500). Equal protein loading was verified by staining blots 
with Ponceau Red and probing for GAPDH or β-Actin. 
2.2.6 Southern analysis 
Genomic DNA was isolated from frozen lymphoma tissue, digested with EcoR1 
(10 mg per sample) and fractionated by agarose gel electrophoresis. Thereafter, DNA 
was transferred to membranes and probed with a radiolabeled heavy chain J3-J4 joining 
region genomic fragment, as described before (147). 
2.2.7 Flow cytometry 
Eµ-Myc lymphoma surface expression of B220, IgM, IgD, CD43, and CD138 were 
assessed with flow cytometry, using the following reagents: Mouse BD Fc block (BD 
Pharmingen 553142) and antibodies (B220-APC BD Pharmingen 553092, IgM-FITC BD 
Pharmingen 553437, IgD-PE BD Pharmingen 558597, CD43-FITC BD Pharmingen 
553270, and CD138-PE BD Pharmingen 553714). Cells were washed, incubated with 
block then antibody, washed again, and fixed prior to assessment on a Becton Dickenson 
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FACSCanto II flow cytometer. Data were analyzed with FlowJo (Tree Star, Inc.). We also 
stained and performed flow cytometry on pooled bone marrow, mesenteric lymph node 
and spleen cells from healthy C57BL/6 mice, which were used as a normalization control 
between experiments. 
2.2.8 Statistical analyses 
Statistical analyses were performed with the statistical environment R using 
standard packages and the pamr and survival packages. Binary regression modeling 
was performed using MATLAB (21). Pathway signature scores were generated using the 
ScoreSignature module in GenePattern (156). Progression free survival was calculated as 
days from therapy to when the mouse had consistent progression of illness compared to 
the day of therapy, was moribund and sacrificed, or died. 
2.2.9 Trp53 sequence analysis 
RNA was isolated from frozen lymphoma cell pellets: cells were lysed in Qiagen 
RLT buffer, the lysate homogenized by passage through a 20 gauge needle followed by a 
QIAshredder spin column, and the RNA purified using an RNeasy spin column 
(Qiagen).  The preparation was treated with DNase I (New England Biolabs) and then 
further purified using a second RNeasy spin column.  The RNA was analyzed for 
quality using the RNA 6000 Pico Kit and the Agilent 2100 Bioanalyzer (Agilent 
Technologies).  RNA (1 µg) was reverse-transcribed using the qScript cDNA SuperMix 
(Quanta BioSciences).  The coding region of the Trp53 cDNA was PCR amplified in three 
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overlapping segments using the Phusion High Fidelity PCR Master Mix with HF Buffer 
(New England Biolabs).  The size and quantity of the PCR products were verified by 
agarose electrophoresis.  The PCR products were treated with ExoSAP-IT (Affimetrix) 
and Sanger sequenced.  FinchTV was used for the chromatogram analysis.  Sequences 
were analyzed for mismatches and insertions or deletions using BioEdit and the Basic 
Local Alignment Search Tool (BLAST) hosted by the NCBI. 
 
2.3 Results  
2.3.1 A method to predict Eμ-Myc lymphoma subtypes 
We previously described the intrinsic heterogeneity of global gene expression in 
lymphomas that develop from the Eµ-Myc mouse model (143). Our current 
unsupervised analysis of gene expression profiling data from 112 Eµ-Myc lymphomas 
confirms variation in overall genomic expression (Figure 1A), and identifies a natural 
division of these lymphomas into two Eµ-Myc subgroups, or “clusters” (Figure 1B).  
Iterative unsupervised k-means clustering analyses demonstrate reproducibility (99.9% 
of runs), whereas attempts to subdivide the dataset into more than two clusters resulted 
in instability in the cluster assignments for the samples. 
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Figure 1. Unsupervised clustering of Eμ-Myc lymphomas 
A) Heatmap of the Eµ-Myc lymphoma training set, with lymphomas clustered based on 
similarities in expression of the 2% of probes with the highest standard deviation across 
all samples. Data was centered and scaled; red color represents upregulated gene probes 
and blue color represents downregulated gene probes. B) The first and second principal 
component (PC) of gene expression array data from each Eµ-Myc lymphoma in the 
training set are plotted, grouped using k-means clustering by color into Cluster 1 (red) 
and Cluster 2 (blue).  Plus sign represents the k-means clustering centroid.  This 
demonstrates two distinct genomic clusters defined by an unsupervised clustering 
method. 
 
Moving beyond descriptive analyses, we developed a prediction model (or 
“signature”) that can be used to classify a new lymphoma sample into one of the two 
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clusters (Figure 2A).  This 500-probe cluster classification signature has 97% accuracy of 
correctly classifying training data on leave-one-out cross validation. We evaluated a test 
set of 76 new Eµ-Myc lymphomas, originating in C57BL/6 congenic mice, in which the 
genomic signature identified 56 Cluster 1 lymphomas and 20 Cluster 2 lymphomas, 
using a cut-off score of 0.5. Concordant with the prior description (143), there is a 
significant difference in time to onset of these two types of lymphoma, with Cluster 1 
lymphomas more likely to occur at an earlier age than Cluster 2 lymphomas (median 
time to onset of 121 vs. 326 days, respectively, p = 0.0003, log-rank test, Figure 2B). 
 
Figure 2. Two clusters of Eμ-Myc lymphomas with differential survival 
A) Heatmap of the 500-probe genomic signature that discriminates Cluster 1 and Cluster 
2 Eµ-Myc lymphomas, with samples in columns and probes in rows. Color scheme as in 
Figure 1A. B) Kaplan-Meier curves evaluating time from birth to onset of lymphoma for 
Eµ-Myc mice, grouped by genomic lymphoma cluster (Cluster 1: n=56, Cluster 2: n=20). 
Significance determined by the log-rank test. 
 
 33 
These results confirm heterogeneity in the transgenic Eµ-Myc model and 
establish a predictive framework that can prospectively evaluate new and independent 
Eµ-Myc lymphomas. 
2.3.2 Genetic, biologic, and clinical differences between the Eμ-Myc 
subtypes 
Moving beyond simply classifying Eµ-Myc lymphomas, we evaluated differences 
between the identified genomic clusters.  For example, in supervised analyses of 
differentially expressed genes between the two clusters, we found that genes 
upregulated in Cluster 1 lymphomas are significantly enriched for gene ontology 
biological function terms related to RNA processing, regulation of transcription and 
translation, and cell cycle, whereas genes upregulated in Cluster 2 lymphomas are 
significantly enriched for gene ontology biological function terms that include immune 
response, protein localization, and regulation of apoptosis (p values all < 10-8; Bonferroni 
FWER all < 10-5, Table 3).   
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Table 3: Highest Gene Ontology Biological Processes Terms that are 
significantly upregulated in Cluster 1 vs. Cluster 2 Eμ-Myc lymphomas 
Gene Ontology Term Upregulated in Eµ-
Myc Lymphoma 
Cluster 
Nominal P-value Bonferonni value 
RNA processing Cluster 1 1.92E-111 5.99E-108 
mRNA metabolic process Cluster 1 3.92E-76 1.22E-72 
mRNA processing Cluster 1 1.97E-75 6.14E-72 
RNA splicing Cluster 1 1.47E-69 4.60E-66 
Cell cycle Cluster 1 1.23E-59 3.83E-56 
DNA metabolic process Cluster 1 1.99E-57 6.22E-54 
Immune response Cluster 2 4.68E-20 1.46E-16 
Protein localization Cluster 2 2.06E-11 6.42E-08 
Establishment of protein 
localization 
Cluster 2 
8.24E-11 2.56E-07 
Protein transport Cluster 2 1.14E-10 3.56E-07 
Vesicle-mediated transport Cluster 2  2.54E-10 7.90E-07 
Regulation of apoptosis Cluster 2  4.08E-09 1.27E-05 
 
A further evaluation of gene expression data identified significant differences 
between the Eµ-Myc lymphoma clusters in terms of gene sets that represent B-cell 
maturation.  Using a stage-specific genomic signature developed from sorted murine B-
cells of different maturation stages (157), we classified Eµ-Myc lymphomas as pro/pre B-
cell stage (n = 53, 70%), follicular/marginal zone stage (n = 14, 18%) and germinal center 
B-cell stage (n = 9, 12%).  Lymphomas classified as deriving from pro/pre B-cells were 
more common in the Cluster 1 subgroup, whereas lymphomas classified as from the 
follicular/marginal zone stage were more common in Cluster 2 subgroup (p = 5x10-7, 
Chi-squared test, Table 4).    
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Table 4: Distribution of Eμ-Myc lymphomas with regard to B-cell maturation 
stage, determined by genomic analyses 
 Cluster 1 
(n = 56) 
Cluster 2 
(n = 20) 
Pro/Pre B-cell 48 5 
Follicular/Marginal Zone B-cell 3 11 
Germinal Center B-cell 5 4 
 
Since stage of differentiation and activation has prognostic value in human 
DLBCL (10), we evaluated the Eµ-Myc lymphoma genomic data within the context of 
germinal center B-cell (GCB) versus activated B-cell (ABC) lymphoma subtypes.  While 
there is variation in the stage of differentiation of DLBCL, BL arise uniformly from B-
cells at the GCB stage (134, 158). Using genomic data from human lymphoma samples 
(159), we evaluated a GCB/ABC genomic signature in human and Eµ-Myc lymphomas 
(Figure 3A).  In an independent dataset of human DLBCL samples (135), the signature 
correctly distinguished lymphomas annotated as GCB or ABC type (Figure 3B, p < 2x10-
16, Wilcoxon rank-sum test), and when a cut-off score of 0.5 was used, the accuracy was 
94% (n=329/350).  Applying this signature to Eµ-Myc lymphoma data identified 
significant differences between the two cluster subtypes (Figure 3C, respective median 
scores 0.18 vs. 0.99, where 0 represents GCB and 1 represents ABC, p < 0.0001, Wilcoxon 
rank-sum test). Using a cut-off score of 0.5, Cluster 1 lymphomas were more likely to 
have a GCB score, while Cluster 2 lymphomas were more likely to have an ABC score (p 
= 0.0001, Pearson’s Chi-squared test).  These different supervised analyses of genomic 
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data underscore the distinct differences between Eµ-Myc lymphomas and suggest there 
is variation in cell of origin maturation and differentiation. 
 
 
Figure 3. GCB/ABC expression patterns segregate in Eμ-Myc lymphomas 
A) Heatmap of the genomic signature that discriminates germinal center B-cell (GCB) 
from activated B-cell (ABC) lymphomas. Red color represents upregulated gene probes 
and blue color represents downregulated gene probes. B) Box and whisker plot of GCB-
ABC signature scores in an independent dataset of human B-cell lymphomas, grouped 
by GCB or ABC lymphoma type. Signature score of 0 represents GCB, while 1 represents 
ABC. Bold line represents median, box represents the interquartile range (IQR), 
whiskers represent 1.5 times the IQR, and dots represent outliers. P value calculated 
using the Wilcoxon rank sum test. C) Box and whisker plot of GCB-ABC signature 
scores in Cluster 1 and Cluster 2 Eµ-Myc lymphomas. Graphing parameters as described 
in Figure 3B.  p-value calculated by Wilcoxon rank sum test. 
 
Our prior work linked Eµ-Myc lymphoma subgroups with human aggressive 
lymphoma subtypes.  We evaluated genomic data from aggressive human lymphomas 
(the BL to DLBCL spectrum) and confirmed that the genomic signature we developed to 
classify Eµ-Myc lymphomas significantly differentiates molecularly defined human 
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aggressive B-cell lymphoma subtypes (where a score of zero represents Cluster 1 and a 
score of one represents Cluster 2). BL is most similar to Cluster 1 Eµ-Myc lymphomas, 
while DLBCL (non-molecular BL) is most similar to Cluster 2 Eµ-Myc lymphomas 
(Figure 4). Together with the analysis of genomic data with regards to GCB versus ABC 
distinction, these results define Cluster 1 Eµ-Myc lymphoma as a representation of 
human BL and Cluster 2 Eµ-Myc lymphoma as a representation of the ABC subtype of 
human DLBCL. 
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Figure 4. Eμ-Myc signature segregates human aggressive disease 
Box and whisker plot of Eµ-Myc signature scores in three types of aggressive human B-
cell lymphomas (data from GSE4475 dataset). Bold line represents median, box 
represents the interquartile range (IQR), whiskers represent 1.5 times the IQR, and dots 
represent outliers. P value calculated using the Kruskal-Wallis test. 
 
In an additional evaluation of complexity in the Eμ-myc model, we performed 
array CGH on DNA from 74 Eμ-myc lymphomas (50 Cluster 1 and 24 Cluster 2). We 
found significant differences between Cluster 1 and Cluster 2 lymphoma in alterations at 
chromosomes 3, 4, 7, 14, and 15 (Figure 5). For example, one region on chromosome 14 
was significantly deleted in Cluster 2 lymphomas, while another region on chromosome 
15 was significantly amplified in Cluster 2 lymphomas. Notably, many genes identified 
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within these regions are altered in human B-cell lymphomas. For example, the deleted 
region of chromosome 14 in Cluster 2 Eμ-myc lymphomas contained genes known to be 
deleted or mutated in DLBCL, including Tnfrsf10b and Dock5 (160, 161). Additionally, 
the amplified region of chromosome 15 in Cluster 2 Eμ-myc lymphomas contained genes 
known to be mutated and/or constitutively activated in DLBCL, such as Irak4, Skp2, and 
Pim3 (162-164). Thus, recurrent chromosomal alterations underscore the heterogeneity 
observed in the Eμ-myc model and identify common genetic alterations between murine 
and human lymphomas. 
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Figure 5. Array CGH of Eμ-Myc lymphomas 
Top: The proportion of lymphomas in Cluster 1 (top) and Cluster 2 (middle) with copy 
number aberration, in order by genes on the chromosomes. High copy amplifications 
denote 2 or more extra copies at a specific locus. Bottom: Analysis of significant copy 
number differences between Cluster 1 and Cluster 2 lymphomas. A cut-off q-value 
(determined by false-discovery rate) of 0.2 was used to determine genes with significant 
copy number changes (bottom). This cut-off is represented by the dotted red line.  These 
results identify chromosomal regions with significantly different rates of amplification 
or deletion between the two transcriptionally-defined lymphoma clusters. 
 
In addition to genomic evaluations of Eμ-myc lymphomas, we assessed surface 
expression of B-cell markers by flow cytometry.  While individual lymphomas varied in 
expression of IgM, IgD, CD43, and CD138, we found no significant difference between 
the Eμ-myc lymphoma clusters in terms of surface marker expression. 
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We also evaluated the mutational status of the Trp53 gene and the overall status 
of the p53-p19ARF-MDM2 tumor suppressor axis in representative clones of the two Eµ-
Myc clusters, as past work has documented mutation of p53 in over a quarter of Eµ-Myc 
lymphomas and overall disruption of the p53-p19ARF-MDM2 tumor suppressor axis in 
about 80% of lymphomas arising in this mouse model (63). Five out of seven Cluster 1 
lymphomas harbored mutation in the Trp53 cDNA, including extensive deletions and 
others that would lead to missense amino acid substitutions or frameshifts, while all 
seven of the Cluster 2 lymphomas evaluated contained wild type Trp53 cDNA (p = 0.026, 
Chi-squared test) (Table 5).  In addition, one of the Cluster 1 lymphomas with wild type 
p53 exhibited elevation of MDM2 expression, whereas the other had elevated p19ARF 
expression.  Five of the Cluster 2 lymphomas exhibited moderate elevation of p19ARF 
expression, two had moderate increase in MDM2 expression, and one had substantial 
increase in MDM2 expression (Figure 6).  As such, it appears that Trp53 gene disruption 
is an additional distinction between the two lymphoma clusters.  However, given the 
observed heterogeneity within and between the lymphoma clusters with regards to 
mutation of Trp53 and expression of p19ARF and MDM2, Trp53 mutation status and the 
p53 tumor suppressor axis do not appear to be the sole determinants of the differences 
between the clusters. 
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Table 5: Trp53 mutation status 
Lymphoma Clone Trp53 status 
C1-1 L124P 
C1-2 Wild type 
C1-3 Y120R with 2 nucleotide insertion 
C1-4 Deletion of exons 2 through 7 
C1-5 Wild type 
C1-6 R242C 
C1-7 No product – presumed deletion of locus 
 
C2-1 through C2-7 Wild type 
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Figure 6. p53 axis protein expression 
Immunoblots for p53, p19ARF, and MDM2 protein expression in fourteen spontaneously 
arising Eµ-Myc lymphomas from the new cohort (seven Cluster 1 and seven Cluster 2).  
A sample from the original Eµ-Myc cohort served as a positive control.  GAPDH 
expression demonstrates equal protein loading. 
 
In addition to genomic evaluations of Eµ-Myc lymphomas, we assessed surface 
expression of B-cell markers by flow cytometry.  While individual lymphomas varied in 
expression of IgM, IgD, CD43, and CD138, we found no significant difference between 
the Eµ-Myc lymphoma clusters in terms of surface marker expression (data not shown). 
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From a clinical perspective, Eµ-Myc lymphomas are classically described as 
presenting with diffuse lymphadenopathy (70). We observed this presentation in the 
majority of Eµ-Myc lymphomas, but also found sick mice with a single enlarged lymph 
node, mediastinal disease, or gut-centered disease.  Cluster 1 lymphomas were 
significantly more likely to present with lymphadenopathy that was diffuse or involving 
more than one lymph node region, whereas Cluster 2 lymphomas were significantly 
more likely to present with lymphadenopathy isolated to one lymph node group, 
particularly gut-centered (p = 0.0005, Pearson’s Chi-squared test, Table 6).  
 
Table 6: Distribution of Eμ-Myc lymphomas with regard to phenotype 
 Cluster 1 
(n = 56) 
Cluster 2 
(n = 20) 
Diffuse lymphadenopathy 45 6 
Mediastinal, isolated 7 3 
Gut infiltration, isolated 0 8 
Mediastinal and gut 4 3 
 
 
Taken together, our evaluations of Eµ-Myc lymphomas categorized into two 
clusters based on gene expression patterns not only describe biological and clinical 
differences between the clusters but also link them to distinct human lymphoma entities.  
Thus, genomic heterogeneity within the transgenic Eµ-Myc mouse model appears to 
mirror genomic heterogeneity in human lymphomas. 
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2.3.3 Eμ-Myc lymphomas exhibit variation in chemotherapy response 
that reflects variation in chemotherapy response of human 
aggressive lymphomas 
Human aggressive B-cell lymphomas display heterogeneity with regards to 
response to therapy. Within DLBCL, clinical markers (IPI score (165, 166)) or molecular 
markers (ABC vs. GCB type (10)) distinguish patients with variable responses to multi-
agent chemotherapy or chemo-immunotherapy. BL is uniformly treated with high-dose 
multi-agent regimens (167), and retrospective analyses revealed that DLBCLs that are 
genomically similar to BL have improved outcomes when treated intensively like BL 
(134).  
Given the links between human aggressive B-cell lymphomas and the Eµ-Myc 
model, we were interested in determining the extent to which the Eµ-Myc model could 
be used to model heterogeneity in response to lymphoma therapy.  We used gene 
expression signatures as a method by which to generate hypotheses regarding therapy 
response, and followed these analyses with experimental testing using Eµ-Myc tumors. 
We began by utilizing a genomic signature developed to distinguish lymphomas 
that are sensitive or resistant to CHOP-like chemotherapy regimens (Figure 7A) (159). 
Interestingly, MYC was differentially expressed in the 200-probe signature, being more 
highly expressed in CHOP-resistant lymphomas (10.1 vs. 9.1 median RMA expression 
value, p = 0.0001, Wilcoxon rank sum test). This is notable because MYC+ DLBCLs have 
inferior outcomes to standard chemotherapy compared to other DLBCLs (168). Single 
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genes which are known to modulate chemotherapy sensitivity in the Eµ-Myc model 
(which include Top2a, Akt, Bcl-2, p53, Pten, and p19ARF (83, 146, 149-152) were not present 
in the CHOP response signature, but two probes for AKT3 and three probes for PTEN 
were differentially expressed between CHOP sensitive and CHOP resistant lymphomas 
at nominal p-values between 0.01 to 0.05 (Wilcoxon rank sum test). When this genomic 
signature is applied to an independent dataset of DLBCL patients treated with either 
CHOP or CHOP with rituximab (R-CHOP) (135), the signature significantly separated 
groups of patients with distinct responses to these two regimens (Figures 7B and 7C). 
We next evaluated the genomic signature of CHOP resistance in the Eµ-Myc lymphoma 
samples. As shown in Figure 7D, Cluster 2 lymphomas were predicted to be more 
chemotherapy sensitive than Cluster 1 lymphomas (p < 0.0001, Wilcoxon rank-sum test).  
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Figure 7. Differential predicted sensitivity to CHOP regimen 
A) Heatmap of the genomic signature that discriminates human lymphomas with the 
longest remission after CHOP chemotherapy (“sensitive”) to those with the shortest 
remission (“resistant”). Red color represents upregulated gene probes and blue color 
represents downregulated gene probes. Overall survival of DLBCL patients after 
treatment with CHOP (B) or R-CHOP (C), grouped by CHOP signature score. P value 
calculated by log-rank test. D) Box and whisker plot of CHOP signature scores in Cluster 
1 and Cluster 2 Eµ-Myc lymphomas. Parameters as described in Figure 3A. p-value 
calculated by Wilcoxon rank-sum test. 
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To validate the genomic predictions of differential sensitivity to chemotherapy 
between Cluster 1 and Cluster 2 Eµ-Myc lymphoma, we tested selected Eµ-Myc 
lymphoma clones for response to single agent doxorubicin and cyclophosphamide in 
vivo. These studies rely on the transplantability of Eμ-Myc lymphomas into 
immunocompetent C57BL/6 background strain mice.  We selected lymphomas (C1-1, 
C1-3, C1-4, C1-5, C2-1, and C2-2) that were representative of the two clusters and that 
retained their characteristics after transplantation into recipient mice.  These 
characteristics include genomic signature scores (Figure 8A), expression of B cell surface 
markers (Figure 8B), clonality as defined by single immunoglobulin heavy chain 
rearrangement (Figure 8C), and MYC, p53, p19ARF, and MDM2 protein expression 
(Figures 8D and 8E). As such, the transplanted tumors appear to represent valid models 
of the two forms of Eµ-Myc lymphoma.  
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Figure 8. Consistency between original Eμ-Myc lymphoma and recipients 
A) Cellular and oncogenic pathway activity signature scores from Cluster 1-1 lymphoma 
(left graph) or Cluster 2-1 lymphoma (right graph) plotted against scores from 
lymphomas derived in recipient mice from these lymphomas.  P value calculated from 
Pearson’s correlation.  These findings indicate that transcriptional programs of pathway 
activity are not altered by transplantation into a new mouse. B) Surface expression of 
B220, CD43, CD138, IgM, and IgD in C1-1 and C2-1 lymphomas and their representative 
recipients, demonstrating stability in expression of these markers between the primary 
and the transplanted lymphomas. C) Southern blots probing for size of JH3-JH4 B-cell 
receptor fragment in germline DNA: C1-1 and its transplanted recipient lymphomas, 
and C2-1 and its transplanted recipient lymphomas.  This result shows that these 
monoclonal lymphoma clones are maintained after transplantation. D) Immunoblot for 
MYC protein expression in C1-1 and C2-1 and the transplanted recipient lymphomas, 
demonstrating maintained MYC expression after transplantation.  GAPDH expression 
demonstrates equal protein loading. E) Immunoblots for p53, p19ARF, and MDM2 protein 
expression in C1-1 and C2-1 and the transplanted recipient lymphomas, demonstrating 
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stability in p53 axis perturbations after transplantation.  GAPDH expression 
demonstrates equal protein loading. 
 
 
Eµ-Myc lymphoma recipients were treated with single agent doxorubicin or 
cyclophosphamide with one-time dosing, as previously described (149). As shown in 
Figure 9, therapeutic responses correlated with genomic signature predictions of CHOP 
resistance: mice bearing the Cluster 2-type Eµ-Myc lymphoma had significantly longer 
responses with either of the single agent conventional chemotherapy agents than mice 
bearing the Cluster 1-type lymphoma. After doxorubicin treatment, mice bearing the 
Cluster 1 lymphomas C1-1 (n = 7), C1-3 (n = 5), C1-4 (n = 5), or C1-5 (n = 6) continued to 
have ill appearance and rapid progression of lymphoma.  On the other hand, almost all 
the mice bearing the Cluster 2 lymphomas C2-1 (n = 4) or C2-2 (n = 4) improved to 
normal appearance for approximately two weeks prior to progression.  After 
cyclophosphamide therapy, mice bearing the Cluster 1 lymphomas C1-1 (n = 9), C1-3 (n 
= 7), C1-4 (n = 6), or C1-5 (n = 6) returned to a healthy appearance for approximately 
three weeks prior to progression.  However, mice bearing the Cluster 2 lymphomas C2-1 
(n = 5) or C2-2 (n = 4) returned to a fully healthy appearance for approximately five 
weeks prior to progression.  As a negative control, mice bearing either Cluster 1 or 
Cluster 2 lymphomas that were not treated had progressive disease and were sacrificed 
one to two days from when treatment would have been administered.  Upon dissection, 
there was a severe burden of lymphoma in all mice (data not shown). 
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Figure 9. Eμ-Myc lymphoma response to chemotherapy 
A) Progression free survival in recipient mice bearing Cluster 1 lymphomas (red) 
compared to Cluster 2 lymphomas (blue) after treatment with doxorubicin.  B) 
Progression free survival in recipient mice bearing Cluster 1 lymphomas (red) compared 
to Cluster 2 lymphomas (blue) after treatment with cyclophosphamide.  p-values 
calculated using the log-rank test. 
 
The selected Eμ-Myc lymphoma clones are representative of the lymphoma 
clusters in terms of predictions of chemotherapy response, based on the CHOP 
resistance genomic signature.  The Cluster 1-type lymphomas C1-1, C1-3, C1-4, and C1-5 
had a CHOP resistance signature score of 0.8, 0.97, 0.94, and 0.98 respectively, while the 
Cluster 2-type lymphoma C2-1 and C2-2 had a CHOP resistance signature score of 0.35 
and 0.02.  These scores correlate with the chemotherapy responses shown in Figure 9.   
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Since perturbations of the p53 tumor suppressor axis are associated with inferior 
response to conventional chemotherapy in aggressive human lymphomas (169, 170) and 
in Eμ-Myc lymphomas (83), we also evaluated the response to chemotherapy based on 
the status of p53.  As noted above, each of the Cluster 2 lymphomas exhibited wild type 
Trp53 whereas the majority of the Cluster 1 lymphomas contained a mutant or deleted 
Trp53 gene.  Nevertheless, there were examples of Cluster 1 lymphomas that did contain 
a wild type Trp53 gene, and as seen in Figures 10A and 10B, the response to 
chemotherapy for a Cluster 1 Trp53 wild type was more similar to the Cluster 1 with 
mutant Trp53 rather than the Cluster 2 lymphomas. This suggests that p53 status is 
likely not the sole determinant of response to chemotherapy in this model.  
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Figure 10. p53 status and chemotherapy response 
Progression free survival in recipient mice bearing Cluster 1 lymphomas that have p53 
mutation or deletion (red solid line) compared to Cluster 1 lymphomas that are p53 
wild-type (“WT,” red dashed line) and Cluster 2 lymphomas (blue solid line) after 
treatment with doxorubicin (A) and cyclophosphamide (B). p-values calculated using 
the log-rank test. 
 
 
Together, these findings support the concept that variation in therapy response 
exists in transgenic Eµ-Myc mice.  Additionally, transcriptional programs shared 
between human aggressive B-cell lymphomas and Eµ-Myc mice appear to serve as 
predictive biomarkers of response to conventional chemotherapy.  As such, Eµ-Myc 
mice have utility as a model for variation in therapeutic response in human lymphomas, 
and for this reason, Eµ-Myc mice might be able to identify novel targets to rationally 
select and design treatment for human aggressive B-cell lymphomas. 
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2.3.4 Evaluating pathway specific targeted therapies in the context of 
Eμ-Myc lymphoma heterogeneity 
Our prior work and the work of others defined gene expression signatures of 
cellular pathway activity and demonstrated that these signatures can serve as predictive 
biomarkers of response to pathway-specific targeted therapies (20, 21, 171). As shown in 
Figure 11A, we found significant distinctions in cellular pathway activity between types 
of human aggressive B-cell lymphomas, with RAS, MYC, PI3K, and E2F1 pathways 
significantly upregulated in BL, while TGFβ, STAT3, TNFα, EGFR, and interferon 
pathways are significantly upregulated in DLBCL (non-molecular BL). Visually, a 
similar pattern of pathway activity is seen between Cluster 1 and Cluster 2 Eµ-Myc 
lymphoma samples as is seen between BL and DLBCL (Figure 11B). To quantitate the 
similarity, we calculated binary logistic regression coefficients of the genomic signatures 
with respect to the human and Eµ-Myc lymphoma, and found a significant correlation 
between the coefficients for the lymphomas (cor = 0.961, Pearson’s correlation test, 
Figure 11C).  
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Figure 11. Patterns of pathway activation in Eμ-Myc lymphomas and human disease 
A) Heatmap of scores from cellular and oncogenic pathway activity signatures in 
molecularly defined Burkitt lymphoma (BL) compared to diffuse large cell lymphoma 
(DLBCL). Red represents upregulated pathways and blue represents downregulated 
pathways. B) Heatmap, with color scheme as in Figure 11A, comparing Cluster 1 and 
Cluster 2 Eµ-Myc lymphomas from the training set. C) Binary regression coefficients 
from fitting each pathway activity signature scores to the phenotype of BL vs. DLBCL 
are plotted against binary regression coefficients from fitting each pathway activity 
signature score to the phenotype of Cluster 1 vs. Cluster 2, and were compared using 
Pearson’s correlation. 
 
 
Our goal in this research is to use these genomic signatures of pathway activity 
to identify novel therapeutic targets for cancers.  To initiate these studies in lymphoma, 
we began by evaluating the NF-κB pathway, a known oncogenic pathway in DLBCL.  
We evaluated a genomic signature of the NF-κB pathway in human and Eµ-Myc 
lymphoma, and thereafter tested the extent to which therapeutic inhibition of the NF-κB 
pathway is beneficial in specific subgroups of lymphoma.   
In human aggressive B-cell lymphomas, the NF-κB pathway appears to have 
divergent functions.  For example, in DLBCL, NF-κB pathway is a well-recognized pro-
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survival and oncogenic mechanism (172), while in BL, the NF-κB pathway appears to act 
in a pro-apoptotic fashion within the context of MYC overexpression (173). The central 
role of the NF-κB pathway in DLBCL has led to the clinical evaluation of bortezomib, a 
proteosome inhibitor that suppresses the NF-κB pathway, where there appears to be 
specific efficacy in the ABC subtype of DLBCL (174, 175). Because of the variable role 
and activity of the NF-κB pathway in the spectrum of human aggressive B-cell 
lymphomas, we hypothesized that the same might be seen in Eμ-Myc lymphomas. 
To assess NF-κB pathway activity in Eμ-Myc lymphomas, we utilized a genomic 
signature of the “TNFα pathway,” which was developed from gene expression data 
obtained from endothelial cells treated with TNFα (GSE9055(176)) and is known to 
reflect activation of the NF-κB pathway.  Using this genomic signature, we found 
significantly higher predictions of NF-κB pathway activity in the Cluster 2 Eµ-Myc 
lymphomas compared to the Cluster 1 lymphomas (Figure 12A, p < 0.0001). The 
predictions of differential NF-κB pathway activity between the two lymphoma clusters 
is supported by finding elevated protein expression of phosphorylated p65/RELA in 
Cluster 2 lymphomas compared to Cluster 1 (Figure 12B and Table 7) and by differential 
mRNA expression of NF-κB target genes between the two lymphoma clusters (Table 8).  
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Figure 12. NF-κB pathway in Eμ-Myc lymphomas 
A) Box and whisker plot of the NF-κB signature scores comparing Cluster 1 and Cluster 
2 Eµ-Myc lymphomas.  Bold line represents median, box represents the interquartile 
range (IQR), whiskers represent 1.5 times the IQR, and dots represent outliers. p-value 
calculated using the Wilcoxon rank sum test. B) Immunoblots for phosphorylated p65 
(RELA) and total p65 protein expression in six Eμ-Myc lymphomas (three Cluster 1 and 
three Cluster 2) showing a higher level of phosphorylated p65 in Cluster 2 Eμ-Myc 
lymphomas, supporting the prediction of higher NF-κB activity in this group of 
lymphomas. 
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Table 7: Eμ-Myc lymphoma TNFa signature 
Lymphoma TNFa signature score 
C1-1 0.35 
C1-3 0.25 
C1-4 0.18 
C1-5 0.29 
C2-1 0.84 
C2-2 0.80 
C2-6 0.90 
 
 
Table 8: mRNA expression of selected NF-κB target genes in Cluster 1 and Cluster 2 
Eμ-Myc lymphomas 
Gene Name Affymetrix Probe 
ID 
Median Cluster 1 
expression 
Median Cluster 2 
expression 
P-value 
(Wilcoxon rank-
sum test) 
Tnfsf13b (Baff) 1460255_at 5.7027 6.5399 1.976321e-06 
Blimp1 (Prdm1) 1420425_at 5.5224 7.1433 1.876977e-11 
Ccl4 1421578_at 6.6616 7.336 2.346668e-10 
Cd40 1439221_s_at 6.2323 6.381 0.005841444 
Il2ra 1420692_at 4.8648 5.2171 2.540128e-05 
B2m 1449289_a_at 12.9391 13.464 6.416793e-08 
Cd44 1452483_a_at 7.9538 8.6154 1.975549e-05 
Abca1 1421839_at 6.2129 6.7607 1.581027e-08 
Fas 1460251_at 5.5219 5.8393 0.0002021305 
Pim1 1423006_at 7.1451 7.9762 4.425071e-11 
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Because of the differential NF-κB pathway activity in the two Eµ-Myc lymphoma 
clusters, we hypothesized that therapeutic inhibition of the NF-κB pathway would be 
more beneficial in mice bearing Cluster 2 Eµ-Myc lymphomas than in mice bearing 
Cluster 1 Eµ-Myc lymphomas.  As bortezomib is known to inhibit the NF-κB pathway 
(177) and has been evaluated in human aggressive lymphomas, we tested Eµ-Myc 
lymphoma Cluster 1 and Cluster 2 clones for their response to bortezomib. 
As seen in Figure 13A, single agent bortezomib therapy was significantly more 
effective in mice bearing the Cluster 2 Eµ-Myc lymphomas than Cluster 1 Eµ-Myc 
lymphomas.  The recipients of Cluster 2 lymphomas C2-1 (n = 6) and C2-2 (n = 8) treated 
with bortezomib had stabilization of disease for approximately one to two weeks, while 
recipients of Cluster 1 lymphomas C1-1 (n = 6), C1-3 (n = 6), C1-4 (n = 6), and C1-5 (n = 6) 
treated with bortezomib almost uniformly progressed within days of the first injection.  
As with cyclophosphamide and doxorubicin, Cluster 2 lymphomas (all Trp53 wild type) 
had longer progression free survival than Cluster 1 lymphomas (either Trp53 wild type 
or mutant/deleted) after bortezomib treatment (Figure 13B). The NF-κB pathway 
signature scores for the Cluster 2 lymphomas (0.84 and 0.8 respectively) were higher 
than the NF-κB pathway signature scores for the Cluster 1 lymphomas (0.35, 0.25, 0.18, 
and 0.29 respectively), and the scores correlated with the clinical responses seen. 
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Figure 13. Eμ-Myc response to bortezomib 
A) Progression free survival in recipient mice bearing Cluster 1 lymphomas (red) 
compared to Cluster 2 lymphomas (blue) after treatment with bortezomib.  p-values 
calculated using the log-rank test. B) Progression free survival in recipient mice bearing 
Cluster 1 lymphomas that have p53 mutation or deletion (red solid line) compared to 
Cluster 1 lymphomas that are p53 wild-type (“WT,” red dashed line) and Cluster 2 
lymphomas (blue solid line) after treatment with bortezmib. 
 
 
The results of applying and testing genomic signatures of pathway activity to the 
Eµ-Myc model demonstrate that they can be used as biomarkers of therapeutic response.  
Since Eµ-Myc lymphoma is a model for heterogeneity seen in human aggressive B-cell 
lymphomas, and since mouse and human lymphomas have similar patterns of pathway 
activity as measured by genomic signatures, we believe that Eµ-Myc mice can serve as a 
model to identify and test novel targeted therapies for human aggressive B-cell 
lymphoma subtypes. 
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2.4 Discussion  
Perhaps the greatest challenge facing the development of new drugs and 
effective treatment for human cancers is the heterogeneity of the disease. Cancer in 
general is not one disease, and the same holds true for B-cell lymphomas. BL, DLBCL, 
and B-cell lymphomas with features intermediate between DLBCL and BL represent a 
spectrum that exhibits clinical heterogeneity and diversity of underlying genetic 
alterations. An ability to define and understand this heterogeneity is clearly critical to 
adapting and applying effective treatment strategies to individual patients.  
Equally important to attaining the goal of personalized lymphoma therapy is the 
development of disease models that can be used for the evaluation of new therapeutic 
strategies. The Eµ-Myc transgenic mouse was developed as an example of B-cell 
lymphoma initiated by the Myc oncogene, and various studies have used this model to 
investigate how the manipulation of cooperating genes can alter time to lymphoma 
onset or modulate response to chemotherapy (74, 83, 144, 146, 149-151). However, the 
naturally inherent heterogeneity of the model is not well appreciated.  
Our prior studies highlighted the fact that the Eµ-Myc model develops a variety 
of genomically diverse lymphomas that occur naturally and have distinct differences in 
time to lymphoma onset (143). Here, we confirm these findings and develop methods 
that can be used to classify new lymphomas and link them to distinct human lymphoma 
subtypes.  A key and critical component of our approach is the capacity to use gene 
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expression profiling as a common currency to allow for cross-species comparisons (69). 
Genomic signatures developed in the human context and applied to mouse data, and 
vice versa, demonstrate similarities in biology between human and murine lymphomas. 
Even though all Eµ-Myc lymphomas derive from Myc-overexpressing B-cells and 
human B-cell lymphomas do not necessarily have MYC aberrations, our approach shows 
that additional genomic programs connect human and murine lymphomas.  
Although the Eµ-Myc model shares genomic programs with aggressive human 
B-cell lymphomas, it does have certain limitations.  Recent next generation sequencing 
efforts have identified numerous mutations that are found with varying frequency in 
human aggressive lymphomas (140-142). Although we do not know the extent to which 
the Eµ-Myc model recapitulates the full breadth of genetic alterations in human disease, 
the resulting gene expression patterns demonstrate the downstream similarities between 
human and murine lymphomas.  In addition, we note differences comparing the 
subtypes of Eµ-Myc and human aggressive lymphoma, such as presentation (localized 
vs. extensive disease), cell of origin determination (GCB vs. ABC subtypes), and 
response to chemotherapy.  These differences highlight that the mouse model is not an 
exact representation of aggressive human lymphomas.  Despite these limitations, we 
believe our approach provides the rationale for using Eµ-Myc mice and genomic 
signatures to model heterogeneity of therapy response in aggressive human B-cell 
lymphomas. 
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Most importantly, we now shift the focus of these studies from purely 
descriptive to one where Eµ-Myc mice can serve as a model to test therapies that may 
have future utility in human aggressive lymphomas.  Our evaluation of conventional 
chemotherapy drugs used in the treatment of lymphoma validates that Eµ-Myc mice can 
serve to model heterogeneity in response to therapy in the human setting. Aberration in 
the p53 gene, resulting in abnormal protein expression, is known to modulate the 
response of lymphomas to conventional chemotherapy.  Our evaluation of the p53 axis 
in Eµ-Myc mice confirms these findings since all of the p53 mutations were found in 
Cluster 1 lymphomas, which displayed the greatest resistance to chemotherapy.  
Nevertheless, our work suggests that additional genetic programs may affect 
chemotherapy response in the Eµ-Myc mouse model since one cluster 1 lymphoma with 
wild type p53 also exhibited chemotherapy resistance.  However, this limited analysis 
with only one such clone precludes conclusions regarding the relative roles of p53 status 
versus expression-based clusters in predicting therapeutic response. Further 
experiments with additional lymphoma clones as well as with other conventional 
chemotherapy agents will be necessary to fully assess this.  
Our previous work and that of others have established a link between pathway 
activation and sensitivity to pathway-specific therapeutic agents (20, 171). Using the Eµ-
Myc model to evaluate targeted therapeutics in different subtypes of lymphoma holds 
great promise.  In experiments beginning to explore these possibilities, we observed that 
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treatment with bortezomib, a proteosome inhibitor that suppresses NF-κB pathway 
activity, had preferential benefit in treating lymphomas derived from the Cluster 2 
subgroup, which we demonstrate has having similarities to the ABC-subtype of DLBCL. 
These data confirm results emerging from human clinical trials regarding the use of 
bortezomib-containing regimens in the ABC subgroup of DLBCL (174, 175). Moving 
forward, our results suggest that predictions of pathway activity could be used to select 
and test new therapeutic options and combinations in an in vivo experimental model 
that reflects characteristics of subtypes of human lymphoma. Ultimately, such findings 
could inform patient stratification and design of future clinical trials. 
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3. Genomic analysis of the role of NFYB in E2F1-
mediated apoptosis 
3.1 Introduction 
E2Fs are a family of transcription factors important for the regulation of cell 
proliferation and apoptosis. E2F activation, resulting from cyclin-dependent kinase 
inhibition of retinoblastoma (Rb) protein function, is the trigger that leads to the 
transition from G0 to G1-S and initiation of the cell cycle. Genetic lesions in the Rb tumor 
suppressor pathway lead to unrestrained E2F activity and deregulated cell proliferation, 
critical to the development of numerous cancers (178-180). Among the three activator 
E2Fs, E2F1-E2F3, E2F1 is unique in its ability to induce apoptosis as well as proliferation 
(181). Overexpression of E2F1 in quiescent fibroblasts induces apoptosis (182) while 
E2F1-/- mouse thymocytes are resistant to apoptotic stimuli (183). The induction of 
numerous apoptotic genes and the repression of survival genes have been documented 
during E2F1-dependent apoptosis (120, 123, 184-187). Additionally, DNA damage leads 
to E2F1 stabilization through ATM -mediated phosphorylation and activation through 
PCAF-mediated acetylation, resulting in apoptosis (123, 124). Together, these studies 
suggest an important role of E2F1 deregulation in cancer as well as the therapeutic 
potential to harness the apoptotic activity of E2F1 for cancer therapy. However, better 
understanding of the control mechanisms balancing the proliferative and apoptotic 
activities of E2F1 is necessary to realize this potential.  
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Previous studies have demonstrated that E2F1 induces numerous other 
transcription factors, some of which cooperate with E2F1 during induction of target 
genes. For example, E2F1 induces and then cooperates with FOXO1/3 to induce 
apoptotic genes (128). In contrast, E2F1 induces TopBP1, which binds to E2F1 and 
specifically represses its apoptotic activity (188). These examples underscore the 
importance of other transcriptional regulators in determining the transcriptional and 
phenotypic outcomes of E2F1. 
The nuclear transcription factor Y (NF-Y) recognizes and binds to the CCAAT 
box, which is highly enriched in the promoters of genes regulated during the G2/M 
phase (189, 190). NF-Y is a trimeric complex that is composed of NFYA, NFYB, and 
NFYC subunits, all of which are necessary for DNA binding. NFYB and NFYC contain a 
histone-like motif and form a dimer which is required for association with NFYA and 
sequence-specific DNA binding (191). The NF-Y complex plays a role in regulating 
proliferation by controlling expression of genes required for cell cycle progression such 
as cyclin A, cyclin B2, CDC25A, CDC25C, and CDK1 (192-195). Furthermore, NF-Y 
regulates cell survival through direct control of several anti-apoptotic genes (196, 197). 
Paradoxically, ectopic expression of NFYA was recently shown to induce apoptosis 
through upregulation of E2F1 (198). 
In this chapter, I will present data that support an inverse relationship, whereby 
E2F1 induces the expression of NFYB, which, together with E2F1, regulates a large 
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group of joint target genes. These NFYB-dependent E2F1 target genes including many 
apoptotic genes that, based on gene expression, contribute to a pro-survival role for 
NFYB in E2F1-mediated apoptosis.  Furthermore, we show that overexpression of these 
genes occurs in sarcomas compared to normal control tissues and associates with 
chemotherapy resistance. Taken together, our results identify NFYB as a new important 
pro-survival player in E2F1 transcriptional program. 
3.2 Materials and Methods 
3.2.1 Cell culture 
U2OS human osteosarcoma cells stably expressing ER-HA-E2F1 were grown in 
Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum (FBS) and 2.5ug/ml 
puromycin. U2OS cells stably expressing ER-HA-E2F1 and overexpressing NFYB were 
grown in the same media along with 10ug/ml blasticidin. 4-Hydroxytamoxifen (OHT) 
was obtained from Sigma (T176) and dissolved in ethanol. 
3.2.2 RNA isolation and RT-PCR 
Total RNA was isolated using RNeasy Kit (Qiagen) on a QIAcube (Qiagen). RNA 
quality and concentration was assessed using Nanodrop ND-1000 Spectrophotometer. A 
total of 1ug RNA was reverse transcribed using High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies 4368814) according to manufacturer’s instructions. 
cDNA was diluted 1:4 with water. cDNA was analyzed in triplicate by real time PCR on 
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Life Technologies StepOnePlus Real-Time PCR Systems with Life Technologies Power 
SYBR Green  Master Mix (4367659). 
3.2.3 Chromatin immunoprecipitation 
ER-HA-E2F1 chromatin immunoprecipitations were conducted using the EZ-
ChIP Kit from Millipore (17-371) according to the manufacturer’s instructions using 
monoclonal anti-HA antibody (Covance 16B12). NFYB (GPH1017391(-)01A), SFRP1 
(GPH1026162 (+)01A), PRKCZ (GPH1000044(-)01A), FOLH1 (GPH1016343(-)01A), and 
IGX1A (GPH100001C(-)01A) EpiTect ChIP primers were obtained from Qiagen. 
Immunoprecipitated DNA was analyzed in quadruplicate by real time PCR on an ABI 
Prism 7900HT Sequence Detection System with RT2 SYBR Green ROX qPCR Mastermix 
(Qiagen 330520). 
3.2.4 Microarray analysis 
RNA for microarray analysis of U2OS ER-HA-E2F1 cells was prepared using the 
RNeasy Kit (Qiagen) on a QIAcube (Qiagen). RNA quality and integrity was analyzed 
using Agilent Lab-on-a-Chip RNA Bioanalyzer. RNA was amplified using Ambion 
Message-Amp Premier Kit and analyzed on Affymetrix U133A 2.0 microarrays by the 
Duke Microarray Facility. Raw microarray data was normalized using the MAS5 
algorithm or RMA algorithm. Expression data is available in the Gene Expression 
Omnibus database under accession number GSE61272.  
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Unsupervised clustering was performed using Cluster 3.0. The MAS5 
normalized data was log transformed, mean-centered by gene, and normalized by gene. 
Hierarchical clustering was performed by clustering genes using correlation 
(uncentered) similarity metric and complete linkage. Clustering results were viewed and 
figures generated using Java Treeview. 
Pathway signatures were generated using the ScoreSignature module in 
GenePattern4 using MAS5 and RMA normalized microarray data. Pathway signatures 
were clustered by pathway in Cluster 3.0 using correlation (uncentered) similarity 
metric and complete linkage. Heatmap was generated using Matlab software.  
3.2.5 siRNA and lentivirus infection 
siRNA reverse transfections were performed using Lipofectamine RNAiMax 
reagent (Life Technologies 13778150). Negative control siRNAs were from Sigma 
(SIC001) and Dharmacon (D-001810-01). siRNAs targeting NFYB were from Dharmacon 
(J-010002-08) and Ambion (4392420). 
V5-tagged NFYB driven by CMV promoter overexpression vector was obtained 
from DNASU (HsCD00329598). Lentiviral particles were produced using 293T cells co-
transfected with the lentiviral vector, pMD2.G (Addgene 12259), and psPAX2 (Addgene 
12260) using Mirus TransIT-LT1 Transfection Reagent (MIR 2300). U2OS ER-HA-E2F1 
cells were infected followed by selection with blasticidin (10ug/ml) for two weeks. 
                                                     
4 http://www.broadinstitute.org/cancer/software/genepattern/ 
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3.2.6 Western blotting 
Cell pellets were lysed with RIPA buffer containing Complete Mini protease 
inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor cocktail (Roche). 
Proteins were resolved on 10% SDS-PAGE, transferred to Immobilon PVDF membranes 
and probed with antibodies against GAPDH (Santa Cruz, Sc-25778), NFYB (Santa Cruz, 
Sc-13045), cleaved PARP (Cell Signaling, 9541S), and V5 (Pierce, MA5-15253). Equal 
protein loading was verified by probing for GAPDH. 
3.2.7 Statistical analysis 
Graphs and significance levels were generated using Graphpad software. Pooled 
results are presented as mean and standard deviation of triplicate experiments for 
expression-based real time PCR and quadruplicate experiments for chromatin 
immunoprecipitation-derived real time PCR. For determining the list of genes regulated 
by NFYB, p values were calculated using two tailed t-test with unequal variance. 
3.2.8 Oncomine analysis 
The list of genes generated from the microarray analysis (Appendix A) was 
entered into Oncomine Research Premium Edition as a custom concept and analyzed for 
associations across all Oncomine datasets with the following thresholds: p-value of 1E-4 
and odds ratio of 2. 
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3.3 Results 
3.3.1 NFYB is a direct target of E2F1 
Previous work has documented the role of E2F transcription factors in the 
control of gene expression central to cell cycle and cell fate decisions (115). Further work 
has provided evidence for a complex combinatorial mechanism of gene regulation 
involving E2F proteins together with other cooperating transcriptional regulators (127, 
199, 200). This includes regulatory cascades in which E2Fs activate the expression of 
genes encoding other transcription factors and then cooperate with these induced factors 
to regulate additional target genes, a relationship know as a feed-forward regulatory 
loop (128, 201). To further explore this concept, with a focus on the E2F1 transcription 
factor, we have made use of an inducible system with an ER-E2F1 chimeric protein 
expressed in U2OS cells. Upon the addition of 4-hydroxytamoxifen (OHT), the chimeric 
protein translocates to the nucleus and activates E2F1-mediated transcription. These 
cells have been previously characterized showing minimal effect of OHT on the original 
parental cell line (106, 128). 
In a recent study of E2F1 target genes, we found that genes encoding 
transcription factors represent over 13% of E2F1 target genes with “Regulation of 
Transcription” as a significantly enriched Gene Ontology (GO) category (p<0.0001) (128). 
Among the transcription factors induced by E2F1, we have focused on NFYB since NFY 
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proteins, similar to E2F1, are important regulators of both proliferation and apoptosis 
(reviewed in (202)). 
To validate the microarray results showing induction of NFYB by E2F1, we 
analyzed NFYB expression levels by real-time PCR. Following OHT induction, NFYB 
expression increased linearly through four and eight hours to reach a level almost seven-
fold higher than prior to E2F1 induction (Figure 14A). This induction of NFYB RNA is 
also reflected at the protein level by Western blotting where the induction of NFYB 
protein can be seen at eight and twenty four hours following OHT induction (Figure 
14B).  
To address whether NFYB induction is a direct effect of the action of E2F1, we 
performed a chromatin-immunoprecipitation (ChIP) analysis to determine whether E2F1 
binds to the NFYB promoter. Following induction by OHT, E2F1 binding to the NFYB 
promoter increased more than four-fold while binding to IGX1, a negative control, did 
not change (Figure 14C). This suggests that activation of NFYB transcription results from 
direct binding of E2F1 to the NFYB promoter.  
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Figure 14. NFYB is a direct E2F1 target 
A) Real-time PCR analysis of NFYB mRNA levels at four and eight hours after E2F1 
induction in U2OS ER-E2F1 cells. Cells were serum starved for twenty four hours prior 
to addition of 80 nM OHT. B) Western blot of NFYB and GAPDH protein levels. U2OS 
ER-E2F1 cells were induced with 80nM OHT for eight and twenty four hours following 
twenty four hour serum starvation. Lysates were analyzed by SDS-PAGE/Western blot 
and probed with anti-NFYB and anti-GAPDH antibodies (loading control). C) U2OS ER-
E2F1 cells were serum starved for twenty four hours followed by induction with 80nM 
OHT for seven hours. Chromatin immunoprecipitation was performed with anti-HA 
antibody for detection of ER-HA E2F1 binding to the NFYB promoter and IGX1 repeats 
(negative control). 
 
 
 
 
 
3.3.2 Role of NFYB in E2F1-mediated transcriptional activation 
To explore the role of NFYB in E2F1-mediated transcriptional activation, we 
knocked down the expression of NFYB using two different small interfering RNA 
(siRNAs) targeting NFYB. Efficient knockdown of NFYB mRNA levels was validated by 
real-time PCR (Figure 15A) and Western blot analysis (Figure 15B).  
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Figure 15. NFYB mRNA and protein knockdown 
A) Real-time PCR analysis of NFYB mRNA levels following siRNA transfection. U2OS 
ER-E2F1 cells were transfected with two siRNAs targeting NFYB or two negative control 
siRNAs at 100nM. Cells were serum starved for twenty four hours followed by 80nM 
OHT induction for four or eight hours. B) Western blot analysis of NFYB protein levels 
following E2F1 activation. U2OS ER-E2F1 cells transfected with siRNA targeting NFYB 
or control siRNAs were serum starved for twenty four hours followed by OHT 
induction for eight, twenty four, and forty eight hours. Lysates were analyzed by SDS-
PAGE/Western blot and probed with anti-NFYB and anti-GAPDH antibodies (loading 
control). 
 
We next interrogated the global gene expression effects of NFYB knockdown on 
E2F1-mediated transcription using expression microarrays. Comparison of genome-
wide expression levels after E2F1 activation in cells transfected with either negative 
control siRNAs or siRNAs targeting NFYB identified 197 genes whose expression in 
E2F1 activated cells (after 8 hours of OHT induction) was significantly different 
(p<0.001) following NFYB knockdown by at least 1.3 fold higher or 0.7 fold lower 
compared to control siRNA. As expression of these genes is affected by NFYB 
knockdown and given that E2F1 directly targets NFYB, these genes represent the 
broadest spectrum of genes directly or indirectly targeted by E2F1 and NFYB. 
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Unsupervised clustering of these genes reveals five clusters of genes: 1) induced by E2F1 
activation and reduced by NFYB knockdown, 2) unaffected by E2F1 activation and 
reduced by NFYB knockdown, 3) reduced by E2F1 activation and further reduced by 
NFYB knockdown, 4) induced by E2F1 activation and further induced by NFYB 
knockdown, 5) reduced by E2F1 but higher in NFYB knockdown (Figure 16A and 
Appendix A).  
Further examination of the genes within the clusters also revealed multiple genes 
involved in apoptosis and survival. For example, the genes within cluster 2, whose 
expression reduced by NFYB knockdown, include API5, an inhibitor of E2F1-mediated 
apoptosis, and MALT1, a paracaspase that promotes activation of NF-κB signaling (129, 
203). Cluster 4, in which expression was induced by E2F1 and further increased by 
NFYB knockdown, includes SIVA1, apoptosis inducing factor, a proapoptotic gene that 
plays an important role in CD27-mediated apoptosis (204) and is known to be induced 
by E2F1 (205). We have used RT-PCR to validate the expression of API5 (Figure 16B) and 
SIVA1 (Figure 16C).  
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Figure 16. NFYB target genes and validation 
A) Microarray analysis of the effect of NFYB knockdown on E2F1-mediated 
transcription. Samples were processed in the same manner as in Figure 2A and analyzed 
using Human U133A 2.0 expression microarrays. Heatmap represents the results of 
hierarchical clustering of 224 probes that showed at least 1.3-fold increase or 0.7-fold 
decrease in expression (significance of p<0.001) compared to control following NFYB 
knockdown at eight hours. B) Real-time PCR validation of target gene expression 
decrease for API5. C) Real-time PCR validation of target gene increase for SIVA1. 
Samples were processed in the same manner as Figure 15A. * denotes p<0.05, ** denotes 
p<0.01, *** denotes p<0.001, **** denotes p<0.0001. 
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In order to better understand the transcriptional program directly regulated by 
E2F1 that is dependent upon NFYB, we expanded our analysis of cluster one. Further 
analysis of microarray data identified 148 genes whose expression is induced at least 
two fold by E2F1 activation and is twenty percent higher (significance at p<0.05) in 
induced control siRNA samples compared to induced siNFYB samples (Figure 17A and 
Appendix B). To further validate these genes that may be co-regulated by E2F1 and 
NFYB, we used real-time RT-PCR to measure the expression of those genes in which the 
effect of NFYB knockdown on expression levels was most significant. Validation for 
selected genes is presented for SFRP1 (Figure 17B), FOLH1 (Figure 17C), and PRKCZ 
(Figure 17D).  
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Figure 17. E2F1 and NFYB co-regulated genes 
A) Heatmap represents expression levels of 174 probes that were upregulated at least 
two-fold after eight hours of E2F1 induction in control samples and levels of which were 
at least 20% lower (significant at p<0.05) in siNFYB than in si-control samples in eight 
hours samples. B) Real-time PCR validation of target gene expression decrease for 
SFRP1 following NFYB knockdown. C) Real-time PCR validation of target gene 
expression decrease for FOLH1 following NFYB knockdown. D) Real-time PCR 
validation of target gene expression decrease for PRKCZ following NFYB knockdown. 
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3.3.3 Effect of E2F1 and NFYB on predicted pathway activity 
To determine what pathways are affected by E2F1 induction and NFYB 
knockdown, we performed a pathway analysis using the microarray data. Taking 
advantage of oncogenic, tumor suppressor, and tumor microenvironment signatures 
generated by the Nevins and Chi labs (20, 27), we assessed the likelihood that various 
pathways are activated (Figure 18A) using the ScoreSignature module in GenePattern. 
The effect of E2F1 induction by OHT was validated with the E2F1 pathway 
predictions, showing low E2F1 activity prior to induction for both control and NFYB 
knockdown samples. In both groups, pathway activity increased dramatically following 
OHT induction, with peak induction seen at eight hours. Other pathways that paralleled 
this induction patterns were β-catenin (BCAT), p63, and SRC. Interestingly, BCAT and 
p63 show significantly higher predicted levels of activity in NFYB knockdown samples 
at zero and four hours for BCAT (Figure 18B) and all time points for p63. This suggests 
that NFYB has a strong effect on these pathways during the course of E2F1 induction. 
Other pathways showed an inverse effect, in which predicted pathway activity 
decreased following E2F1 induction. These pathways included EGFR, HER2, Myc, ER, 
PR, interferon α, and interferon β. However, NFYB knockdown has little effect on 
pathway status. Taken together, this data indicates that NFYB plays a role in pathway 
activity following induction by E2F1. 
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Figure 18. Patterns of pathway activation following NFYB knockdown 
A) Heatmap of pathway signatures generated by ScoreSignature for all microarray 
samples. Blue denotes low probability and red denotes high probability. B) Predicted β-
catenin pathway activity as compared between control and NFYB knockdown samples.  
  
Earlier we showed that SFRP1 expression was induced following E2F1 activation 
and that this expression decreases following knockdown of NFYB. SFRP1 is a secreted 
protein that acts as an antagonist of the Wnt receptor (206), which under normal 
conditions activates the β-catenin pathway. Following NFYB knockdown, SFRP1 
expression decreases and β-catenin pathway activity increases, suggesting the former 
may cause the latter. This is reflected in a comparison between predicted β-catenin 
pathway activity in control and NFYB knockdown samples, in which predicted activity 
is significantly higher in the latter group at zero and four hours and almost significantly 
higher at eight hours (p=0.06) (Figure 18B). This data suggests the NF-Y complex is 
involved in regulation of the β-catenin pathway through SFRP1. Interestingly, many 
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other Wnt/β-catenin pathway genes were also present within the E2F1/NF-Y co-
regulated gene set, hinting at the downstream effects of enhanced pathway activity.  
3.3.4 NFYB-dependent E2F1 target genes 
To establish whether the genes induced by E2F1 in an NFYB dependent manner 
are direct targets of E2F1, we performed chromatin immunoprecipitation (ChIP) analysis 
before and after induction by OHT. All three genes showed increased E2F1 binding to 
their promoters following E2F1 induction (Figure 19A). E2F1 recruitment specificity was 
demonstrated by the lack of E2F1 binding to the IGX1 negative control repeat sequences. 
These results indicate that E2F1 is physically associated with the regulatory regions of 
these genes to regulate their expression. As a complementary approach to further 
validate the involvement of NFYB in induction of these targets, we employed a gain of 
function approach. To this end, we infected the inducible U2OS ER-E2F1 cell line with a 
lentivirus containing NFYB cDNA. Following selection to establish a stable line, we 
validated NFYB ectopic expression by RT-PCR (Figure 19B) and Western blotting 
(Figure 19C).  
To test whether increased expression of NFYB caused induction of the target 
genes, we induced the transgenic and parental line with OHT and compared target gene 
expression. Real-time PCR analysis demonstrated that overexpression of NFYB alone 
induced SFRP1 (Figure 19D) and FOLH1 (Figure 19E). Expression of these genes was 
also higher in NFYB-overexpressing cells following E2F1 induction. Taken together with 
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the siRNA data, these results demonstrate that SFRP1 and FOLH1 are novel targets that 
are co-regulated by E2F1 and NFYB.  
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Figure 19. NFYB-dependent E2F1 targets 
A) ChIP analysis of E2F1 binding to target gene promoters. U2OS ER-HA E2F1 cells 
were serum starved for twenty four hours followed by 80nM OHT induction for seven 
hours. Immunoprecipitation was performed with anti-HA antibody for detection of ER-
HA E2F1 binding to the SFRP1, PRKCZ, FOLH1 promoters and to IGX1 repeats 
(negative control). B) Real-time PCR analysis of NFYB expression. U2OS ER-E2F1 cells 
were infected with lentviruses encoding the NFYB cDNA tagged with V5. A stable line 
was selected using blasticidin resistance for two weeks. This NFYB overexpression line 
is denoted as NFYB. The parental U2OS ER-E2F1 line is denoted as “parental”. Cell lines 
were serum starved for twenty four hours followed by 80nM OHT induction for eight 
hours. C) Western blot analysis of ectopic NFYB expression following establishment of 
stable NFYB overexpression cell line. Lysates were analyzed by western blotting of 
NFYB transgene levels using an anti-V5 antibody, and GAPDH. Samples were processed 
in the same manner as in Figure 19B. D and E) Real-time PCR analysis of SFRP1 (D) and 
FOLH1 (E) in U2OS ER-E2F1 in parental and NFYB overexpressing U2OS ER-E2F1 cell 
lines. Samples were processed in the same manner as in Figure 19B.  
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Given the role that NFYB appears to play in regulating multiple anti-apoptotic 
genes, we sought to determine whether NFYB induction played a role in E2F1-mediated 
apoptosis. Western blot analysis following knockdown of NFYB by two different 
siRNAs demonstrated significantly increased E2F1-induced apoptosis as evidenced by 
the intensity of cleaved PARP protein band (Figure 20 and Fig 15B demonstrating 
knockdown efficiency). Coupled with our microarray data that identified multiple pro-
survival NFYB target genes, this functional result suggests that induction of NFYB by 
E2F1 contributes to the attenuation of the apoptotic arm of E2F1 signaling.  
 
 
Figure 20. NFYB and E2F1-mediated apoptosis 
Western blot analysis of cleaved PARP levels following E2F1 activation. U2OS ER-E2F1 
cells transfected with siRNA targeting NFYB or control siRNAs were serum starved for 
twenty four hours followed by induction at eight, twenty four, and forty eight hours 
following OHT induction. Lysates were analyzed by SDS-PAGE/Western blot and 
probed with anti-cleaved PARP and anti-GAPDH antibodies (loading control). See Fig 
15B for NFYB knockdown efficiency in these samples. 
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3.3.5 Genes from E2F1-NFYB signature are upregulated in sarcoma 
and drug resistant cell lines 
In light of the established roles of E2F and NFY in cancer phenotypes, we sought 
to determine whether the transcriptional program jointly controlled by E2F1 and NFYB 
might define unique cancer states.  Using the results from the microarray analysis, we 
generated an E2F1/NFYB signature comprised of 174 expression probes (148 genes) that 
were at least two fold induced by E2F1 and showed the largest decrease in expression 
following NFYB knockdown (Figure 17A and Appendix B). We made use of the 
Oncomine analysis suite, which integrates genome-wide expression and copy number 
data from more than 700 cancer-related datasets as a rich source of expression data 
coupled with phenotypic information (207). In five independent sarcoma datasets, the 
E2F1/NFYB signature is significantly associated with signatures (concepts) consisting of 
genes that are overexpressed in cancer compared to normal tissue. A representative 
heatmap shows the overexpression of genes from the E2F1/NFY signature in 
dedifferentiated liposarcoma compared to normal adipose tissue (Figure 21A). A second 
representative heatmap shows the overexpression of E2F1/NFY signature genes in 
gastrointestinal stromal tumors compared to normal gastric tissue (Figure 21B).  
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Figure 21. NFYB signature overexpression associates with sarcoma 
A) Oncomine analysis demonstrating upregulation of  genes from the NFYB-dependent 
E2F1 signature in Barretina sarocoma dataset. Heatmap showing higher expression in 
dedifferentiated liposarcoma compared to normal adipose tissue. Red color designates 
high expression and blue color designates low expression. B) Oncomine analysis 
demonstrating upregulation of genes from the NFYB-dependent E2F1 signature in 
gastrointestinal stromal tumor compared to normal gastric tissue. 
 
To determine whether this association is specific for the E2F1/NFYB signature, 
we compared the results to those signatures generated using the Oncomine determined 
concept “Up-regulated genes in human osteosarcoma cell line (U2OS) expressing E2F1 
compared to U2OS controls – Literature-defined Concepts” (E2F1 signature). This 
signature did not show the same enrichment within sarcoma datasets, with only one 
dataset in which the signature significantly associates with a concept overexpressed in 
cancer compared to normal (Figure 22A). Similarly, an E2F1-independent NFYB 
signature in which the top 145 genes that were most strongly downregulated by NFYB 
knockdown showed only one dataset in which the signature significantly associates with 
a concept overexpressed in cancer and one in which it associates with a concept 
underexpressed in cancer. Together with the data showing that NFYB is protective 
against E2F1-mediated apoptosis, these results suggest that the NFYB-dependent E2F1 
transcriptional program we defined may be involved in sarcomagenesis or maintenance.  
The Oncomine analysis further indicated that the E2F1/NFY signature is 
significantly associated with concepts from six independent datasets showing lower 
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expression of the genes in drug sensitive sarcoma cell lines compared with drug 
resistant lines (Figure 22B). This association is not limited to sarcoma, but persists across 
a broad range of cell lines. Two example heatmaps show overexpression of signature 
genes in irinotecan resistant cell lines (Figure 23A) and panobinostat resistant cell lines 
(Figure 23B) compared to sensitive cell lines. We again explored whether this association 
was specific to the joint E2F1/NFY signature by comparing it to similar analysis with the 
NFYB-independent E2F1 signature and E2F1-independent NFYB signature. Unlike the 
joint signature, the separate E2F1 and NFYB signatures did not show a clear association 
with drug resistance (Figure 22).  
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Figure 22. Signature association with disease state and therapy resistance 
A) Number of sarcoma datasets from cancer vs normal Oncomine analysis in which 
signatures (concepts) consisting of differentially expressed genes are significantly 
associated with the indicated signatures. The NFYB-dependent E2F1 signature (Figure 
2D and Supplemental Table 2) is derived from our microarray analysis and described in 
the Results section. The E2F1 (U2OS induced) signature is a concept defined by 
Oncomine based on previously published microarray analysis of genes upregulated in 
U2OS ER-E2F1 cells following OHT induction. The E2F1-independent NFYB signature 
consists of probes (174) which expression is reduced 30% following NFYB knockdown 
regardless of the effect of E2F1 induction. Significance is set at an odds ratio of at least 
two and p value of less than 0.0001. Red indicates number of signatures overexpressed 
in cancer compared to normal cells. Blue represents number of signatures under-
expressed in cancer compared to normal. B) Number of datasets in which concepts from 
therapy sensitivity datasets are significantly associated with the signatures described in 
(A). Significance is set at an odds ratio of at least two and p value of less than 0.0001. Red 
indicates number of signatures overexpressed in drug resistant compared to drug 
sensitive cells. Blue represents number of signatures under-expressed in resistant when 
compared to sensitive cells. 
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Figure 23. NFYB signature overexpression associates with drug therapy resistance 
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A) Oncomine analysis demonstrating upregulation of genes from the NFYB-dependent 
E2F1 signature in in irinotecan resistant cell lines compared to irinotecan sensitive cell 
lines. B) Oncomine analysis demonstrating upregulation of genes from the NFYB-
dependent E2F1 signature in panobinostat resistant cell lines compared to panobinostat 
sensitive cell lines. 
 
In summary, when considered together with data showing NFYB as protective 
against E2F1-mediated apoptosis, this analysis suggests that the joint E2F1/NFYB 
transcriptional program may play a role in cancer resistance to chemotherapy. 
 
3.4 Discussion 
E2Fs play a critical role in many cell functions including proliferation, 
development, and cell death. Among the E2Fs, E2F1 is of particular interest because it 
activates expression of genes involved in both proliferation and apoptosis (208), with 
studies detailing transcription factor partners as helping to determine specificity 
towards one or the other (128). Our study identifies NFYB as a novel direct E2F1 target 
that, in turn, regulates multiple downstream genes.  The regulomes of E2F1 and NFYB 
partially overlap and in the current study we focused on a group of genes that are 
induced by both transcription factors. Based on previously published studies we suggest 
that some of these joint targets are responsible for the attenuation of E2F1-induced 
apoptosis (129, 203), thus suggesting a complex interplay regulating the final apoptotic 
phenotype. Furthermore, in silico analysis of this subset of co-regulated genes suggests 
that the NFYB-dependent E2F1 program is linked with sarcoma as it is significantly 
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associated with signatures upregulated in various types of sarcoma compared to normal 
tissue. This analysis furthermore demonstrates that E2F1/NFY signature is associated 
with chemotherapy resistance. 
In addition to genes induced by both E2F1 and NFYB our clustering analysis also 
identified a group of genes that are reduced by E2F1 in an NFYB-dependent manner (Fig 
16A, cluster 5).  These include multiple mitotic genes, such as cdc25C as well as the other 
two subunits of the NFY complex, NFYA and NFYC. These results may indicate a 
compensatory induction of NFYA and NFYC in response to the depletion of NFYB. 
Additional studies are needed to examine the functional significance of this complex 
interplay between E2F1 and different subunits of the NFY complex in cell cycle 
progression and other biological processes.  
A recent study has shown that E2F1 is transcriptionally induced by ectopic 
NFYA expression and that NFYA binds to the E2F1 promoter (198). Combined with our 
results showing E2F1 induces NFYB by direct binding to its promoter indicates a 
positive feedback loop in which the two transcription factors amplify one another’s 
expression. Notably, however, whereas NFYA was shown to promote apoptosis by 
inducing E2F1, our results suggest a pro-survival function for NFYB. Such opposing 
effects of the two subunits of the NF-Y complex might reveal different aspects of co-
regulation and feedback mechanisms between E2F1 and NF-Y or be a result of different 
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approaches employed (ectopic expression of NFYA in Gurtner et al vs knockdown of the 
endogenous NFYB in our study) or different cell lines used.  
Our results indicated a number of cell cycle genes regulated by NFYB. These 
include CCNB1, CCNB2, CDC25C, CDK2, NEK2, PLK1, AKAP8, and GMNN. Given the 
abundance of CCAAT boxes in the promoters of genes regulated during the G2/M phase, 
this is not surprising. Cyclin B1, Cyclin B, and CDC25C have been shown to be direct 
targets of NF-Y and that this binding changes dynamically through the different phases 
of the cell cycle (192, 193, 209-211). Furthermore, CDK2 is known to phosphorylate 
NFYA and physically associate with NF-Y and that this phosphorylation is essential for 
DNA binding of NF-Y (212) as well as the expression of its target cell cycle regulatory 
genes (213). The microarray data indicates that CCNB1, CCNB2, and CDK2 are 
regulated by NF-Y given that its downregulated following knockdown of NFYB. 
Interestingly, CDC25C expression increases following NFYB knockdown, suggesting 
NF-Y negatively regulates the gene’s transcription. 
Our study also identified several pro- and anti-apoptotic genes regulated by NF-
Y and E2F1. API5, an apoptosis inhibitor, is down-regulated while SIVA1, an apoptosis-
inducing factor, is upregulated following NFYB knockdown. This result seems to match 
phenotypically with our result that cleaved PARP levels increase upon NFYB depletion. 
However, expression of TIMP3 and TNFRSF10B, both pro-apoptotic, also decrease upon 
NFYB knockdown, suggesting a balance between pro and anti-apoptotic factors that 
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under different conditions may change NFYB’s role in E2F1-mediated apoptosis. This 
mirrors the results of studies indicating that NF-Y plays roles in proliferation and 
survival as well as cell death. Further studies to determine the effect that levels of pro 
and anti-apoptotic targets regulated by NFYB and E2F1 have on E2F1-mediated 
apoptosis are necessary to determine the key players of the distinct life or death fates in 
different contexts. 
This study also identified an E2F1 and NFYB co-regulated gene, SFRP1, which 
may mediate upregulation of β-catenin pathway activity following NFYB knockdown 
through inhibition of Wnt. The effect of this regulation can be seen in the components of 
the Wnt/ β-catenin pathway that appear within the co-regulated gene set. The pathway 
may also play an important role in the protective effect of NFYB against E2F1-mediated 
apoptosis given its importance in survival and proliferation (214). However, additional 
studies are needed to determine whether SFRP1 is a direct target of NFYB, whether 
knockdown of SFRP1 directly contributes to β-catenin pathway upregulation, and 
whether SFRP1 mRNA or protein levels inversely correlate with survival as implied by 
the data. 
Finally, we identify a set of genes regulated by E2F1 and NFYB that is 
overexpressed in sarcoma compared to normal tissues. This is intriguing in that the 
inducible E2F1 system used in this study comes from an osteosarcoma cell line, 
indicating that the NFYB-dependent E2F1 transcriptional program may be specific to 
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tissues that have a mesenchymal origin. Further enhancing this idea is the fact that E2F1 
target genes induced in an NFYB-independent manner do not show this association with 
sarcoma. Our results showing NFYB to be protective against E2F1 mediated apoptosis 
moreover suggest this NFYB/E2F1 regulated gene set may be involved in the 
development or survival of sarcoma cells. In addition to its association with sarcoma, a 
subset of NFYB-dependent E2F1 regulated genes is overexpressed in chemotherapy 
resistant cell lines. This is not limited to a narrow range of chemotherapies, as the 
association is found for both a topoisomerase inhibitor (irinotecan) and an HDAC 
inhibitor (panobinostat). Intriguingly, this association does not seem to be limited to 
sarcoma. Unfortunately, the clinical relevance of these associations is limited by the lack 
of publicly available sarcoma datasets with patient survival data. Once such data 
becomes available, potential use of the NFYB/E2F signature can be explored as a 
biomarker for selecting patients that may respond to certain chemotherapies in future 
clinical trials. 
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4. Conclusions 
4.1 Summary 
This thesis describes the utilization of DNA microarrays to study heterogeneity 
in the tumors’ response to targeted therapies and oncogenesis. First, we demonstrated 
Eμ-Myc tumors can be accurately and reproducibly classified into two subgroups. 
Importantly, these two subgroups displayed differences in surface cell staining, 
oncogenic and tumor suppressor protein expression, and copy number changes. We also 
showed that the two subgroups also differed significantly based on their predicted 
signatures for cell of origin and treatment response. By utilizing oncogenic pathway 
signatures, we explored the segregation of patterns of pathway activation between the 
two groups and showed their similarity to gene expression patterns seen in human 
aggressive B cell lymphoma. Finally, we were able to take advantage of the predicted 
pathway status for TNFα to show that pathway scores can predict the likely response to 
a targeted therapy for that specific pathway.  
In studying oncogenic mechanisms, we made use of an inducible E2F1 system 
that recapitulates ectopic E2F1 expression to induce apoptosis. By examining genome-
wide expression following E2F1 activation in this system, we were able to identify NFYB 
as a novel and direct target of E2F1 via chromatin immunoprecipitation. Furthermore, 
we were able to identify an NFYB-dependent E2F1 transcriptional program that 
included a number of pro- and antiapoptotic genes, with SFRP1, API5 and SIVA1 being 
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most interesting in terms of further experimentation. In terms of its direct effect on E2F1-
mediated apoptosis, we showed that NFYB is protective against apoptosis induced by 
ectopic E2F1 expression. We also identified an NFYB-dependent E2F1 signature that, 
based on in silico analysis, is overexpressed in sarcoma, tumors that derive from cells of 
mesenchymal origin. Combined with the fact that NFYB protects cells from E2F1 
induced apoptosis, these data point to the potential roles of the joint E2F1/NFYB 
transcriptional program as being protective against sarcomagenesis and maintenance. 
4.2 Limitations and future directions 
4.2.1 Eμ-Myc heterogeneity 
With every study, there are limitations present that should be addressed in 
future experiments. The heterogeneity present within the Eμ-Myc model is apparent, 
but what drives the heterogeneity is still not well understood. For example, our results 
indicated that Myc protein levels are also different between the two clusters, with cluster 
one tumors having uniformly higher Myc protein relative to cluster two. Given the 
importance of the Myc transcription factor in cellular processes, this segregation could 
play a significant role in cluster differences. How much this plays into the differences in 
patterns of gene expression will need to be empirically determined. A good place to start 
would be to knock down the expression of Myc in cluster one tumors and look at the 
resulting changes in patterns of pathway activation and other gene expression 
characteristics. 
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Traditional treatment of human lymphoma is a multi-agent regimen 
administered over the course of several weeks. The mouse chemotherapy studies 
presented here are single agent single dose administrations that may not reflect the 
combinatorial efficacy seen in human disease. If a safe dosage in mice can be established 
for using multiple agents over several administrations, then these study results should 
be replicated in that context. In the case of heterogeneity in treatment response to 
targeted therapies, the two lymphoma subgroups showed segregation in other 
oncogenic pathways. STAT3, PI3K, and E2F1 all have small molecule drugs targeting 
different pathway components. For example, in the case of E2F1, cyclin dependent 
kinase inhibitors, which prevent E2F activation, would be predicted to have greater 
efficacy in cluster one tumors. Many targeted therapies are also used in combination 
with traditional chemotherapy with enhanced combinatorial effect. This is something 
that can also be tested in the mouse model. We initiated work towards this goal by 
combining cyclophosphamide or doxorubicin with bortezomib, but initial studies were 
limited by death of the mice within a day of drug administration with mice showing 
symptoms similar to tumor lysis syndrome. The confirmation of tumor lysis through 
elevated blood phosphate levels compared to untreated tumor bearing mice indicates 
the possible enhanced efficacy of combining a chemotherapy and targeted therapy.  
Our analysis of the relationship between p53 mutational status and 
chemotherapy resistance also had limitations in the fact that we were only able to test 
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one cluster one tumor with wild type p53. Additional tumors of this type will need to 
tested with a rigorous multivariate analysis. Given that the Western analysis of the p53 
axis proteins showed possibly aberrant expression of ARF and Mdm2 in several cluster 
one and two tumors, the p53 sequencing analysis should be expanded to encompass the 
p53 axis, which includes sequencing ARF and MDM2, as these are also frequently 
mutated. With the decreasing costs of sequencing, it would be incredibly informative to 
conduct transcriptome sequencing of Eμ-Myc tumors as this would not only provide 
expression information, but also show the breadth of mutations that have occurred in 
the expressed portion of the genome. One of the limitations of transcriptome sequencing 
is its inability to show copy number changes. Approaches such as exome sequencing or 
whole genome sequencing would complement RNA sequencing to provide information 
on non-transcribed mutations that may affect gene expression as well as copy number 
alterations, which are commonly seen in all types of cancers. All the aforementioned 
sequencing methods applied over dozens of Eμ-Myc tumors may indicate driver 
mutations through the enrichment of mutations in certain genes. Sequencing data would 
also provide an opportunity to see just how well the mouse model recapitulates the 
mutational landscape of BL and DLBCL. 
4.2.2 NFY in E2F1-mediated apoptosis 
In terms of the relationship between E2F1 and NFYB, I believe we have only 
scratched the surface. I was able to show that several co-regulated genes were direct 
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targets of E2F1, but was unable to do the same for NFY. Given the importance of NFYA 
in recognizing the CCAAT promoter sequence, using NFYB as the immunoprecipitating 
protein may cause many target genes to not be detected. Chromatin 
immunoprecipitation experiments with a tagged NFYA may resolve this issue. An 
alternative strategy would be to use a luciferase assay in which the target gene 
promoters are fused with the luciferase gene. By assaying luciferase intensity following 
NFYB ectopic expression or knockdown may also indicate these genes are direct NF-Y 
targets. Further experiments are needed to see which co-regulated targets are most 
responsible for the protective effect of NFYB against E2F1-mediated apoptosis. 
Knockdown experiments of induced genes would begin to give a better picture of which 
components of E2F1-induced apoptosis are moderated by NF-Y. Additionally, it would 
be interesting to see what role p53 plays, as it is involved in regulation of both 
pathways. Despite the lack of drugs targeting NF-Y components, one can imagine that 
with greater understanding of how E2F1 and NF-Y determine their involvement in 
proliferation or apoptosis, it will eventually be possible for drugs to target the 
proliferative potential of the two transcription factors while leaving the apoptotic 
potential intact. 
The co-regulation of SFRP1, a well-known Wnt/β catenin inhibitor, is interesting 
because of the results from pathway activation analyses showing that β catenin pathway 
activity is predicted to increase following NFYB and hence SFRP1 mRNA knockdown. 
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The effect seems to be short-lived, however, as this difference is only significant at zero 
and four hours, but results at the eight hour timepoint are close to significance. 
Experiments in which SFRP1 levels are knocked down independently of NFYB are 
needed to solidify the link between SFRP1 and β catenin in this cell line. Also assaying 
for apoptosis under modification of SFRP1 levels would indicate whether or not the β 
catenin pathway plays a role in E2F1 mediated apoptosis. 
Furthermore, there is currently a separation between the NF-Y regulome which 
contains apoptotic genes such as API5 and SIVA1 and the NFYB dependent E2F1 
transcriptional program which is linked to sarcoma and drug resistance. The protective 
effect of NFYB in E2F1-mediated apoptosis is the only phenotype linking them. Other 
phenotypic assays such as Caspase Glo or flow cytometry for caspase can confirm the 
cleaved PARP Western results. The role that the apoptotic genes play in both E2F1-
induced apoptosis as well as its enhancement upon knockdown of NFYB can also link 
the two sets of genes. With the NFYB overexpression cell line, it would also be feasible 
to test if overexpression of NFY attenuates E2F1-mediated apoptosis. Initial testing 
based on cleaved PARP Western blotting has indicated that the effect is negligible, but 
alternative assays should be done to confirm this result. 
The Oncomine analysis indicated a connection between the NFYB-dependent 
E2F1 transcriptional program and sarcoma. Interestingly, the U2OS that this inducible 
E2F1 system is based on is derived from an osteosarcoma. It may be because of this that 
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the NFYB-dependent E2F1 concept shows any association at all with sarcoma. To 
establish whether this gene set plays a role in other cancers, it may be necessary to 
recreate the inducible E2F1 system in another cell line and show that inducing E2F1 in 
such a context leads to apoptosis. However, the fact that the coregulated gene set 
associates with sarcoma indicates that the genes may play an important role in 
tumorigenesis of or tumor maintenance in mesenchymal cells. An Oncomine analysis 
should also be run on the NF-Y regulome described in the microarray analysis as this list 
of genes is more extensive than the NFYB concept used in the Oncomine analysis. 
In summary, the work presented in this thesis provides a view of cancer 
heterogeneity and oncogenic mechanisms as recognized through the prism of patterns of 
gene expression that can be used to extrapolate meaningful information for directing 
targeted therapeutics. It is part of the work of developing tools that can make 
personalized medicine more effective. By combining genomic analysis of cancers with 
functional studies of relevant biological pathways to understand the mechanisms behind 
their development, we can begin to harness the potential of individualized medicine. 
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Appendix A 
Table 9: Genes from hierarchical clustering of NFYB regulated genes 
Cluster 1 
 Probe.Set.ID Gene Title 
205359_at A kinase (PRKA) anchor protein 6 
210355_at parathyroid hormone-like hormone 
202948_at interleukin 1 receptor, type I 
215363_x_at folate hydrolase (prostate-specific membrane antigen) 1 
214023_x_at tubulin, beta 2B 
212959_s_at N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 
221761_at adenylosuccinate synthase 
222071_s_at solute carrier organic anion transporter family, member 4C1 
203072_at myosin IE 
209925_at occludin pseudogene; occludin 
207362_at solute carrier family 30 (zinc transporter), member 4 
215446_s_at lysyl oxidase 
204062_s_at unc-51-like kinase 2 (C. elegans) 
202037_s_at secreted frizzled-related protein 1 
202036_s_at secreted frizzled-related protein 1 
201625_s_at insulin induced gene 1 
211478_s_at dipeptidyl-peptidase 4 
216256_at glutamate receptor, metabotropic 8 
216255_s_at glutamate receptor, metabotropic 8 
215245_x_at fragile X mental retardation 1 
203689_s_at fragile X mental retardation 1 
219526_at chromosome 14 open reading frame 169 
214578_s_at 
similar to Rho-associated, coiled-coil containing protein kinase 1; Rho-
associated, coiled-coil containing protein kinase 1 
216205_s_at mitofusin 2 
202460_s_at lipin 2 
206233_at UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 
218129_s_at nuclear transcription factor Y, beta 
218128_at nuclear transcription factor Y, beta 
218127_at nuclear transcription factor Y, beta 
206615_s_at ADAM metallopeptidase domain 22 
204720_s_at DnaJ (Hsp40) homolog, subfamily C, member 6 
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219703_at meiosis-specific nuclear structural 1 
202178_at protein kinase C, zeta 
203429_s_at chromosome 1 open reading frame 9 
211130_x_at ectodysplasin A 
210829_s_at single-stranded DNA binding protein 2 
218223_s_at pleckstrin homology domain containing, family O member 1 
210941_at protocadherin 7 
202842_s_at DnaJ (Hsp40) homolog, subfamily B, member 9 
204479_at osteoclast stimulating factor 1 
212870_at son of sevenless homolog 2 (Drosophila) 
209569_x_at DNA segment on chromosome 4 (unique) 234 expressed sequence 
204160_s_at ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) 
219932_at solute carrier family 27 (fatty acid transporter), member 6 
208964_s_at fatty acid desaturase 1 
208962_s_at fatty acid desaturase 1 
208963_x_at fatty acid desaturase 1 
216167_at leucine rich repeat neuronal 2 
208925_at claudin domain containing 1 
209993_at ATP-binding cassette, sub-family B (MDR/TAP), member 1 
212812_at serine incorporator 5 
 
Cluster 2 
 Probe.Set.ID Gene Title 
211048_s_at protein disulfide isomerase family A, member 4 
218095_s_at transmembrane protein 165 
215489_x_at homer homolog 3 (Drosophila) 
208703_s_at amyloid beta (A4) precursor-like protein 2 
202101_s_at 
v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding 
protein) 
221318_at neurogenic differentiation 4 
203548_s_at lipoprotein lipase 
202516_s_at discs, large homolog 1 (Drosophila) 
217761_at acireductone dioxygenase 1 
217931_at canopy 3 homolog (zebrafish) 
204298_s_at lysyl oxidase 
211804_s_at cyclin-dependent kinase 2 
201761_at 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
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201662_s_at acyl-CoA synthetase long-chain family member 3 
209706_at NK3 homeobox 1 
201063_at reticulocalbin 1, EF-hand calcium binding domain 
203688_at polycystic kidney disease 2 (autosomal dominant) 
201490_s_at peptidylprolyl isomerase F 
219628_at zinc finger, matrin type 3 
213369_at protocadherin 21 
206683_at zinc finger protein 165 
200927_s_at RAB14, member RAS oncogene family 
214959_s_at API5-like 1; apoptosis inhibitor 5 
205573_s_at sorting nexin 7 
206491_s_at N-ethylmaleimide-sensitive factor attachment protein, alpha 
208309_s_at mucosa associated lymphoid tissue lymphoma translocation gene 1 
221781_s_at DnaJ (Hsp40) homolog, subfamily C, member 10 
209232_s_at dynactin 5 (p25) 
 
Cluster 3 
 Probe.Set.ID Gene Title 
219730_at mediator complex subunit 18 
214642_x_at melanoma antigen family A, 5 
203179_at galactose-1-phosphate uridylyltransferase 
215076_s_at collagen, type III, alpha 1 
201852_x_at collagen, type III, alpha 1 
206463_s_at dehydrogenase/reductase (SDR family) member 2 
214079_at dehydrogenase/reductase (SDR family) member 2 
209208_at mannose-P-dolichol utilization defect 1 
204256_at 
ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3-like, yeast) 
210868_s_at 
ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3-like, yeast) 
201399_s_at translocation associated membrane protein 1 
211162_x_at stearoyl-CoA desaturase (delta-9-desaturase) 
202061_s_at sel-1 suppressor of lin-12-like (C. elegans) 
202062_s_at sel-1 suppressor of lin-12-like (C. elegans) 
218396_at vacuolar protein sorting 13 homolog C (S. cerevisiae) 
209295_at tumor necrosis factor receptor superfamily, member 10b 
203827_at WD repeat domain, phosphoinositide interacting 1 
210970_s_at inhibitor of Bruton agammaglobulinemia tyrosine kinase 
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209234_at kinesin family member 1B 
220205_at transmembrane phosphatase with tensin homology 
209198_s_at synaptotagmin XI 
202816_s_at synovial sarcoma translocation, chromosome 18 
201860_s_at plasminogen activator, tissue 
205523_at hyaluronan and proteoglycan link protein 1 
212403_at ubiquitin protein ligase E3B 
209550_at necdin homolog (mouse) 
221730_at collagen, type V, alpha 2 
211080_s_at NIMA (never in mitosis gene a)-related kinase 2 
204641_at NIMA (never in mitosis gene a)-related kinase 2 
219049_at chondroitin sulfate N-acetylgalactosaminyltransferase 1 
208861_s_at 
alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. 
cerevisiae) 
204149_s_at glutathione S-transferase mu 4 
201932_at leucine rich repeat containing 41 
210406_s_at 
RAB6C, member RAS oncogene family; RAB6A, member RAS oncogene family; 
hypothetical LOC100130819; RAB6C-like 
218539_at F-box protein 34 
217188_s_at chromosome 14 open reading frame 1 
207714_s_at 
serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, 
(collagen binding protein 1) 
203069_at synaptic vesicle glycoprotein 2A 
217749_at coatomer protein complex, subunit gamma 
214710_s_at cyclin B1 
209118_s_at tubulin, alpha 1a 
206369_s_at phosphoinositide-3-kinase, catalytic, gamma polypeptide 
203738_at chromosome 5 open reading frame 22 
218124_at retinol saturase (all-trans-retinol 13,14-reductase) 
203211_s_at myotubularin related protein 2 
212613_at butyrophilin, subfamily 3, member A2 
209846_s_at butyrophilin, subfamily 3, member A2 
211063_s_at NCK adaptor protein 1 
204725_s_at NCK adaptor protein 1 
202043_s_at spermine synthase; similar to spermine synthase 
202705_at cyclin B2 
208180_s_at 
histone cluster 1, H4l; histone cluster 1, H4k; histone cluster 4, H4; histone 
cluster 1, H4h; histone cluster 1, H4j; histone cluster 1, H4i; histone cluster 1, 
H4d; histone cluster 1, H4c; histone cluster 1, H4f; histone cluster 1, H4e; 
histone cluster 1, H4b; histone cluster 1, H4a; histone cluster 2, H4a; histone 
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cluster 2, H4b 
203441_s_at cadherin 2, type 1, N-cadherin (neuronal) 
217977_at selenoprotein X, 1 
209079_x_at 
protocadherin gamma subfamily C, 3; protocadherin gamma subfamily C, 5; 
protocadherin gamma subfamily C, 4; protocadherin gamma subfamily A, 12 
211066_x_at 
protocadherin gamma subfamily C, 3; protocadherin gamma subfamily C, 5; 
protocadherin gamma subfamily C, 4; protocadherin gamma subfamily A, 12 
215836_s_at 
protocadherin gamma subfamily C, 3; protocadherin gamma subfamily C, 5; 
protocadherin gamma subfamily C, 4; protocadherin gamma subfamily A, 12 
205717_x_at 
protocadherin gamma subfamily C, 3; protocadherin gamma subfamily C, 5; 
protocadherin gamma subfamily C, 4; protocadherin gamma subfamily A, 12 
211959_at insulin-like growth factor binding protein 5 
212274_at lipin 1 
222209_s_at transmembrane protein 135 
214945_at family with sequence similarity 153, member B 
201633_s_at cytochrome b5 type B (outer mitochondrial membrane) 
202920_at ankyrin 2, neuronal 
204749_at nucleosome assembly protein 1-like 3 
218047_at oxysterol binding protein-like 9 
213645_at enolase superfamily member 1 
201147_s_at TIMP metallopeptidase inhibitor 3 
205822_s_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 
201341_at ectodermal-neural cortex (with BTB-like domain) 
203041_s_at lysosomal-associated membrane protein 2 
218150_at ADP-ribosylation factor-like 5A 
 
Cluster 4 
 Probe.Set.ID Gene Title 
220097_s_at transmembrane protein 104 
209478_at stimulated by retinoic acid 13 homolog (mouse) 
213577_at squalene epoxidase 
203489_at SIVA1, apoptosis-inducing factor 
210792_x_at SIVA1, apoptosis-inducing factor 
213147_at homeobox A10 
208366_at protocadherin 11 X-linked 
220983_s_at sprouty homolog 4 (Drosophila) 
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213089_at ENSG00000219982 
201565_s_at inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
218642_s_at coiled-coil-helix-coiled-coil-helix domain containing 7 
218350_s_at geminin, DNA replication inhibitor 
204790_at SMAD family member 7 
201419_at BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) 
204621_s_at nuclear receptor subfamily 4, group A, member 2 
215599_at glucuronidase, beta pseudogene 
215043_s_at glucuronidase, beta pseudogene 
206565_x_at glucuronidase, beta pseudogene 
204770_at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 
 
Cluster 5 
 Probe.Set.ID Gene Title 
221777_at chromosome 12 open reading frame 52 
218609_s_at nudix (nucleoside diphosphate linked moiety X)-type motif 2 
209223_at NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa 
209682_at Cas-Br-M (murine) ecotropic retroviral transforming sequence b 
215498_s_at mitogen-activated protein kinase kinase 3 
215499_at mitogen-activated protein kinase kinase 3 
203709_at phosphorylase kinase, gamma 2 (testis) 
204218_at chromosome 11 open reading frame 51 
203848_at A kinase (PRKA) anchor protein 8 
203719_at 
excision repair cross-complementing rodent repair deficiency, 
complementation group 1 (includes overlapping antisense sequence) 
202215_s_at nuclear transcription factor Y, gamma 
205828_at matrix metallopeptidase 3 (stromelysin 1, progelatinase) 
40569_at myeloid zinc finger 1 
203931_s_at mitochondrial ribosomal protein L12 
32259_at enhancer of zeste homolog 1 (Drosophila) 
206785_s_at killer cell lectin-like receptor subfamily C, member 1 
203478_at NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa 
218597_s_at CDGSH iron sulfur domain 1 
216852_x_at 
immunoglobulin lambda variable 2-11; immunoglobulin lambda constant 2 
(Kern-Oz- marker); immunoglobulin lambda variable 1-44; immunoglobulin 
lambda constant 1 (Mcg marker); immunoglobulin lambda variable 1-40; 
immunoglobulin lambda variable 3-21; immunoglobulin lambda locus; 
immunoglobulin lambda constant 3 (Kern-Oz+ marker) 
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202736_s_at LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
37462_i_at splicing factor 3a, subunit 2, 66kDa 
202240_at polo-like kinase 1 (Drosophila) 
219053_s_at vacuolar protein sorting 37 homolog C (S. cerevisiae) 
213897_s_at mitochondrial ribosomal protein L23 
214110_s_at lymphocyte-specific protein 1 pseudogene 
218741_at centromere protein M 
215380_s_at gamma-glutamyl cyclotransferase 
218774_at decapping enzyme, scavenger 
215293_s_at post-GPI attachment to proteins 2 
41858_at post-GPI attachment to proteins 2 
220089_at L-2-hydroxyglutarate dehydrogenase 
218866_s_at polymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDa 
204475_at matrix metallopeptidase 1 (interstitial collagenase) 
205167_s_at cell division cycle 25 homolog C (S. pombe) 
217010_s_at cell division cycle 25 homolog C (S. pombe) 
204107_at nuclear transcription factor Y, alpha 
204108_at nuclear transcription factor Y, alpha 
204109_s_at nuclear transcription factor Y, alpha 
33304_at interferon stimulated exonuclease gene 20kDa 
217907_at mitochondrial ribosomal protein L18 
205730_s_at actin binding LIM protein family, member 3 
203880_at COX17 cytochrome c oxidase assembly homolog (S. cerevisiae) 
201774_s_at non-SMC condensin I complex, subunit D2 
215734_at chromosome 19 open reading frame 36 
213893_x_at PMS2 postmeiotic segregation increased 2 (S. cerevisiae)-like 
214756_x_at postmeiotic segregation increased 2-like 1 pseudogene 
217485_x_at postmeiotic segregation increased 2-like 1 pseudogene 
203980_at fatty acid binding protein 4, adipocyte 
214073_at cortactin 
65517_at adaptor-related protein complex 1, mu 2 subunit 
218261_at adaptor-related protein complex 1, mu 2 subunit 
213322_at chromosome 6 open reading frame 130 
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Appendix B 
Table 10: Genes coregulated by E2F1 and NFYB 
Probe.Set.ID Gene Title 
200762_at dihydropyrimidinase-like 2 
201283_s_at trafficking protein, kinesin binding 1 
201688_s_at tumor protein D52 
201689_s_at tumor protein D52 
201693_s_at early growth response 1 
201711_x_at RAN binding protein 2 
202035_s_at secreted frizzled-related protein 1 
202036_s_at secreted frizzled-related protein 1 
202037_s_at secreted frizzled-related protein 1 
202178_at protein kinase C, zeta 
202236_s_at solute carrier family 16 (monocarboxylic acid transporters), member 1 
202583_s_at RAN binding protein 9 
202670_at mitogen-activated protein kinase kinase 1 
202842_s_at DnaJ (Hsp40) homolog, subfamily B, member 9 
202843_at ralA binding protein 1 
202948_at interleukin 1 receptor, type I 
203044_at carbohydrate (chondroitin) synthase 1 
203057_s_at PR domain containing 2, with ZNF domain 
203072_at myosin IE 
203311_s_at ADP-ribosylation factor 6 
203520_s_at zinc finger protein 318 
203625_x_at S-phase kinase-associated protein 2 (p45) 
203641_s_at COBL-like 1 
203689_s_at fragile X mental retardation 1 
203935_at activin A receptor, type I 
204062_s_at unc-51-like kinase 2 (C. elegans) 
204145_at FSHD region gene 1 
204160_s_at ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) 
204161_s_at ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) 
204184_s_at adrenergic, beta, receptor kinase 2 
204194_at BTB and CNC homology 1, basic leucine zipper transcription factor 1 
204249_s_at LIM domain only 2 (rhombotin-like 1) 
204392_at calcium/calmodulin-dependent protein kinase I 
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204479_at osteoclast stimulating factor 1 
204497_at adenylate cyclase 9 
204507_s_at 
protein phosphatase 3 (formerly 2B), regulatory subunit B, 19kDa, alpha 
isoform (calcineurin B, type I) 
204526_s_at TBC1 domain family, member 8 (with GRAM domain) 
204720_s_at DnaJ (Hsp40) homolog, subfamily C, member 6 
204748_at 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase) 
204832_s_at bone morphogenetic protein receptor, type IA 
204953_at synaptosomal-associated protein, 91kDa homolog (mouse) 
204984_at glypican 4 
204989_s_at integrin, beta 4 
205015_s_at transforming growth factor, alpha 
205016_at transforming growth factor, alpha 
205123_s_at transmembrane protein with EGF-like and two follistatin-like domains 1 
205164_at glycine C-acetyltransferase (2-amino-3-ketobutyrate coenzyme A ligase) 
205333_s_at RCE1 homolog, prenyl protein peptidase (S. cerevisiae) 
205462_s_at hippocalcin-like 1 
205478_at protein phosphatase 1, regulatory (inhibitor) subunit 1A 
205789_at CD1d molecule /// CD1d molecule 
205842_s_at Janus kinase 2 (a protein tyrosine kinase) 
205850_s_at gamma-aminobutyric acid (GABA) A receptor, beta 3 
205860_x_at folate hydrolase (prostate-specific membrane antigen) 1 
206159_at growth differentiation factor 10 
206176_at bone morphogenetic protein 6 
206233_at UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 
206456_at gamma-aminobutyric acid (GABA) A receptor, alpha 5 
206511_s_at sine oculis homeobox homolog 2 (Drosophila) 
206615_s_at ADAM metallopeptidase domain 22 
207150_at solute carrier family 18 (vesicular acetylcholine), member 3 
207265_s_at KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 
207275_s_at acyl-CoA synthetase long-chain family member 1 
207362_at solute carrier family 30 (zinc transporter), member 4 
207767_s_at early growth response 4 
207768_at early growth response 4 
207781_s_at zinc finger protein 711 
207824_s_at MYC-associated zinc finger protein (purine-binding transcription factor) 
208237_x_at ADAM metallopeptidase domain 22 
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208244_at bone morphogenetic protein 3 (osteogenic) 
208264_s_at eukaryotic translation initiation factor 3, subunit 1 alpha, 35kDa 
208606_s_at 
wingless-type MMTV integration site family, member 4 /// wingless-type 
MMTV integration site family, member 4 
208652_at protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 
208985_s_at eukaryotic translation initiation factor 3, subunit 1 alpha, 35kDa 
208990_s_at heterogeneous nuclear ribonucleoprotein H3 (2H9) 
209098_s_at jagged 1 (Alagille syndrome) 
209112_at cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
209281_s_at ATPase, Ca++ transporting, plasma membrane 1 
209339_at 
seven in absentia homolog 2 (Drosophila) /// seven in absentia homolog 2 
(Drosophila) 
209347_s_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 
209569_x_at DNA segment on chromosome 4 (unique) 234 expressed sequence 
209570_s_at DNA segment on chromosome 4 (unique) 234 expressed sequence 
209590_at Bone morphogenetic protein 7 (osteogenic protein 1) 
209591_s_at bone morphogenetic protein 7 (osteogenic protein 1) 
209990_s_at gamma-aminobutyric acid (GABA) B receptor, 2 
210021_s_at uracil-DNA glycosylase 2 
210127_at RAB6B, member RAS oncogene family 
210190_at syntaxin 11 
210240_s_at cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
210355_at parathyroid hormone-like hormone 
210447_at glutamate dehydrogenase 2 
210480_s_at myosin VI 
210540_s_at UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4 
210555_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 
210716_s_at 
restin (Reed-Steinberg cell-expressed intermediate filament-associated 
protein) 
210829_s_at single-stranded DNA binding protein 2 
210875_s_at transcription factor 8 (represses interleukin 2 expression) 
211067_s_at growth arrest-specific 7 /// growth arrest-specific 7 
211171_s_at phosphodiesterase 10A 
211379_x_at 
UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, polypeptide 1 
(Globoside blood group) 
211478_s_at dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) 
211631_x_at UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
211812_s_at 
UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, polypeptide 1 
(Globoside blood group) 
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211985_s_at calmodulin 1 (phosphorylase kinase, delta) 
212056_at KIAA0182 
212209_at thyroid hormone receptor associated protein 2 
212435_at tripartite motif-containing 33 
212447_at kelch repeat and BTB (POZ) domain containing 2 
212521_s_at phosphodiesterase 8A 
212750_at protein phosphatase 1, regulatory (inhibitor) subunit 16B 
212812_at Serine incorporator 5 
212870_at Ras association (RalGDS/AF-6) domain family 3 
212930_at ATPase, Ca++ transporting, plasma membrane 1 
212986_s_at tousled-like kinase 2 
213353_at ATP-binding cassette, sub-family A (ABC1), member 5 
213469_at GPI deacylase 
213470_s_at heterogeneous nuclear ribonucleoprotein H1 (H) 
213533_at DNA segment on chromosome 4 (unique) 234 expressed sequence 
213695_at paraoxonase 3 
213906_at v-myb myeloblastosis viral oncogene homolog (avian)-like 1 
214449_s_at ras homolog gene family, member Q 
214543_x_at quaking homolog, KH domain RNA binding (mouse) 
214578_s_at 
similar to Rho-associated protein kinase 1 (Rho-associated, coiled-coil 
containing protein kinase 1) (p160 ROCK-1) (p160ROCK) 
214691_x_at family with sequence similarity 63, member B 
214790_at SUMO1/sentrin specific peptidase 6 
214890_s_at DKFZP564J102 protein 
214954_at sushi domain containing 5 
215245_x_at fragile X mental retardation 1 
215363_x_at folate hydrolase (prostate-specific membrane antigen) 1 
215716_s_at ATPase, Ca++ transporting, plasma membrane 1 
215794_x_at glutamate dehydrogenase 2 
216125_s_at RAN binding protein 9 
216255_s_at glutamate receptor, metabotropic 8 
216256_at glutamate receptor, metabotropic 8 
216350_s_at zinc finger protein 10 
216488_s_at ATPase, Class VI, type 11A 
216521_s_at BRCA1/BRCA2-containing complex, subunit 3 
216627_s_at UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
216870_x_at deleted in lymphocytic leukemia, 2 
216953_s_at Wilms tumor 1 
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217280_x_at gamma-aminobutyric acid (GABA) A receptor, alpha 5 
217644_s_at son of sevenless homolog 2 (Drosophila) 
217920_at mannosidase, alpha, class 1A, member 2 
218127_at nuclear transcription factor Y, beta 
218128_at nuclear transcription factor Y, beta 
218129_s_at nuclear transcription factor Y, beta 
218182_s_at claudin 1 
218223_s_at pleckstrin homology domain containing, family O member 1 
218319_at pellino homolog 1 (Drosophila) 
218499_at Mst3 and SOK1-related kinase 
219312_s_at zinc finger and BTB domain containing 10 
219631_at low density lipoprotein-related protein 12 
219703_at meiosis-specific nuclear structural 1 
219778_at zinc finger protein, multitype 2 
219797_at 
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A 
219864_s_at Down syndrome critical region gene 1-like 2 
219892_at transmembrane 6 superfamily member 1 
219932_at solute carrier family 27 (fatty acid transporter), member 6 
220014_at mesenchymal stem cell protein DSC54 
220120_s_at erythrocyte membrane protein band 4.1 like 4A 
220253_s_at low density lipoprotein-related protein 12 
220254_at low density lipoprotein-related protein 12 
220265_at G protein-coupled receptor 107 
220386_s_at echinoderm microtubule associated protein like 4 
220955_x_at RAB23, member RAS oncogene family 
221039_s_at development and differentiation enhancing factor 1 
221268_s_at 
sphingosine-1-phosphate phosphatase 1 /// sphingosine-1-phosphate 
phosphatase 1 
221428_s_at 
transducin (beta)-like 1X-linked receptor 1 /// transducin (beta)-like 1X-linked 
receptor 1 
221814_at G protein-coupled receptor 124 
222071_s_at solute carrier organic anion transporter family, member 4C1 
222121_at Src homology 3 domain-containing guanine nucleotide exchange factor 
222235_s_at chondroitin sulfate GalNAcT-2  
41577_at protein phosphatase 1, regulatory (inhibitor) subunit 16B 
59644_at BMP2 inducible kinase 
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